Demographic characteristics	N	%

Female gender	243	64.5

 	M	SD	Range

Age at study (years)	25.0	2.1	22.5 - 30.9

Disease characteristics	N	%	 	N	%

Congenital disorder	200	53.1	Daily medicine use	196	52.0

Perceptible disability	159	42.2	Medical aids/devices	184	48.8

Course of illness	 	 	Limitations in fingers/hand	148	39.3

Worse/variable	156	41.4	Limitation of sight	90	23.9

Stable/positive	221	58.6	Limitations of hearing	31	8.2

 	 	 	Able to sit half an hour	350	92.8

 	 	 	Able to stand half an hour	220	58.4

Chronic conditions	N

Visually impaired/blind	51

Spasm	45

Rheumatoid arthritis	45

Epilepsy	31

Back complaints	28

Hearing impaired/deaf	27

Intestinal complaints	21

CFS	20

Lung complaints	20

Accident damage	19

Paralysis	19

Cancer	18

Muscular dystrophy	17

Arthritis	16

Kidney diseases	13

Skin disease	9

Migraine	9

Heart disease	7

Other	119

Demographic characteristics	N	%

Female gender	243	64.5

	M	SD	Range

Age at study (years)	25.0	2.1	22.5 - 30.9

Disease characteristics	N	%		N	%

Congenital disorder	200	53.1	Daily medicine use	196	52.0

Perceptible disability	159	42.2	Medical aids/devices	184	48.8

Course of illness			Limitations in fingers/hand	148	39.3

Worse/variable	156	41.4	Limitation of sight	90	23.9

Stable/positive	221	58.6	Limitations of hearing	31	8.2

			Able to sit half an hour	350	92.8

			Able to stand half an hour	220	58.4

Chronic conditions	N

Visually impaired/blind	51

S	45

Demographic characteristics	N	%

pasm

Rheumatoid arthritis	45

Epilepsy	31

Back complaints	28

Hearing impaired/deaf	27

Intestinal complaints	21

CFS	20

Lung complaints	20

Accident damage	19

Paralysis	19

Cancer	18

Muscular dystrophy	17

Arthritis	16

Kidney diseases	13

Skin disease	9

Migraine	9

Heart disease	7

Other	119


HCH- isomers	Incubation period (days)	Degradation by isolate DAB-1Y (5 μg/mL) in %	Degradation by isolate. DAB-1W(5 μg/mL) in %

α	8	86	93

28	18	10

β	8	12	14

28	35	32

γ	8	94	98

28	30	28

δ	8	80	76

	28	32	28

HCH- isomers	Incubation period (days)

α	8

28

β	8

28

γ	8

28

δ	8

	28

Degradation by isolate DAB-1Y (5 μg/mL) in %	Degradation by isolate. DAB-1W(5 μg/mL) in %

86	93

18	10

12	14

35	32

94	98

30	28

80	76

32	28


	Odd ratio (95% CI)

Crude: Age < 50 years	1

< 50 years	8.14 (3.49~18.98)

 Gender - Male	1

- Female	2.36 (1.12~5.11)

 p-CagA - Sparse	1

- Weak	4.38 (1.15~16.72)

- Strong	8.34 (2.21~31.55)

Age and gender adjusted

 Sparse p-CagA	1

 Weak p-CagA	3.67 (0.93~14.37)

 Strong p-CagA	8.44 (2.08~34.12)

Age, gender and disease adjusted

 Sparse p-CagA	1

 Weak p-CagA	3.93 (0.92~16.94)

 Strong p-CagA	10.45 (2.25~48.48)

	Odd ratio (95% CI)

p-CagA - Sparse	1

- Weak	4.38 (1.15~16.72)

- Strong	8.34 (2.21~31.55)

Age and gender adjusted

Sparse p-CagA	1

Weak p-CagA	3.67 (0.93~14.37)

Strong p-CagA	8.44 (2.08~34.12)

Age, gender and disease adjusted

Sparse p-CagA	1

Weak p-CagA	3.93 (0.92~16.94)

Strong p-CagA	10.45 (2.25~48.48)


Surgery	Pre-surgery	Post-surgery	Median change

Control	0—11.0 ng/mL	NA	NA

Lumpectomy	0.1—15.8 ng/mL	1.0—53.8 ng/mL	4.8

Mastectomy	0.4—7.6 ng/mL	6.4—53.8 ng/mL	14.7


Liver	Estimated ELOVL6 activity	Estimated SCD1 activity	C16:0/C18:2n-6	C16:0

C18:0/C16:0	C18:1/C16:1	C16:1/C16:0	C18:1/C18:0

Adult	Old	Adult	Old	Adult	Old	Adult	Old	Adult	Old	Adult	Old

C1	−0.797	−0.718	−0.865	−0.658	0.970	0.	0.88	0.517**	0		0.5	−0.485**


RNAi

Control day 1

day 3

mtr-4 day 1

day 3

prp-17 day 1

day 3

F43G9.12 day 1

day 3


	Physician	Chiropractor	Physiotherapist	Total N

Gender	Prevalence (%)	S.E.	Freq.	Prevalence (%)	S.E.	Freq.	Prevalence (%)	S.E.	Freq.

Men	25.596	0.0	639613	5.	0	146	5.0	0.	1270	249887

	Physician	Chiropractor	Physiotherapist	Total N

Gender	Prevalence (%)	S.E.	Freq.	Prevalence (%)	S.E.	Freq.	Prevalence (%)	S.E.	Freq.

		28		86	.02	321	9	01	58	1

Women	32.260	0.030	802309	6.36	0.02	158221	8.81	0.02	219067	2486999


Characteristic	All patients no. (%)	Marital status

Married no. (%)	Widowed no. (%)	Never married no. (%)	Divorced no. (%)	P‐value

No. of pati	61077	40527 (66.4)	2768 (4	12889 (2	4893


Possibilities causing anxiety	Frequency	Percentages	Mean state anxiety score

Fear of death	91	82.7	56.3 ± 8.2

Fear of unknown	58	52.7	57.8 ± 8.9

Financial loss due to hospitalization	47	42.7	54.7 ± 8.6

Results of operation	46	41.8	55.7 ± 7.9

Needing blood transfusion	43	39.1	57.4 ± 9.2

Concern about family	43	39.1	56.9 ± 6.9

Postoperative pain	43	39.1	55.7 ± 9.2

Change of environment	41	37.3	55.2 ± 7.7

Long waiting time for operation	40	36.4	54.9 ± 9.0

Unexpected events	39	35.5	55.2 ± 9.2

Being patient and coming to hospital	35	31.8	51.8 ± 8.9

Dependency	34	30.9	55.1 ± 8.7

Fear of physical disability	33	30	53.9 ± 8.7

Fear of complications	31	28.2	53.3. ± 7.3

Cancellations	31	28.2	54.6 ± 9.0

Alteration in body image	26	23.6	56.7 ± 7.5

Possible unknown diagnostic results	24	21.8	53.2 ± 6.6

Lack of information	18	16.4	51.3 ± 8.1

Nil per mouth	16	14.5	55.6 ± 1.0

Harm from doctor or nurse mistake	16	14.5	57.7 ± 8.8

Terminology and language used	16	14.5	53.8 ± 1.2

Sickness and vomiting	15	13.6	53.7 ± 8.3

Fear of not knowing what occurs while unconscious during anesthesia	14	12.7	52.8 ± 9.2

Concern about fellow patient	13	11.8	55.6 ± 9.2

Absence from work	13	11.8	55.7 ± 9.8

Inaccurate information	12	10.9	55.5 ± 8.9

Short waiting time for operation	10	9.1	56.1 ± 7.4

Getting stuck of needle	9	8.2	54.3 ± 1.2

Lack of knowledge of ward	9	8.2	51.3 ± 8.1

Not awakening from anesthesia	8	7.3	55 ± 1.2

Information from previous negative hospital experiences	8	7.3	55 ± 1.2

Familiarity with facilities	7	6.4	58 ± 7.1

Lack of recognition of staff	5	4.5	55.6 ± 6.7

Awareness during surgery	4	3.6	63.3 ± 2.5

Possibilities causing anxiety	Frequency	Percentages	Mean state anxiety score

Lack of knowledge of ward	9	8.2	51.3 ± 8.1

Not awakening from anesthesia	8	7.3	55 ± 1.2

Information from previous negative hospital experiences	8	7.3	55 ± 1.2

Familiarity with facilities	7	6.4	58 ± 7.1

Lack of recognition of staff	5	4.5	55.6 ± 6.7

Awareness during surgery	4	3.6	63.3 ± 2.5


Histone H3 Acetyl K9 1	Histone H3 Tri Methyl K4 2

Blocking solution 3: 5 min	Blocking solution 3: 5 min

primary antibody 1: 1:200 in PBS 5, incubation: 16 h, 4 °C	primary antibody 2: 1:500 in PBS 5, incubation: 16 h, 4 °C

PostBlock 3: 20 min	PostBlock 3: 20 min

HRP Polymer 3: 30 min	HRP Polymer 3: 30 min

Chromogen: DAB 4 (0.5 min)	Chromogen: DAB 4 (1 min)

Histone H3 Acetyl K9 1	Histone H3 Tri Methyl K4 2

PostBlock 3: 20 min	PostBlock 3: 20 min

HRP Polymer 3: 30 min	HRP Polymer 3: 30 min

Chromogen: DAB 4 (0.5 min)	Chromogen: DAB 4 (1 min)


 	 	Target concentration	Mean measured concentration

Net type	Chemical	Units	Mean	Range	Roof	Sides

PermaNet 3.0	Deltamethrin	g/kg	2.8 (sides)	2.1 - 3.5	-	3.1

g/kg	4 (roof)	3.0 - 5.0	3.9	-

Piperonyl butoxide	g/kg	25 (roof)	18.8 - 31.3	18.7	-

PermaNet 2.0	Deltamethrin	mg/m2	55	41.3 - 68.8	69.4	65.6

NetProtect	Deltamethrin	g/kg	1.8	1.4 - 2.3	1.6	1.6

Interceptor	Alpha-cypermethrin	mg/m2	200	150.0 - 250.0	171.0	251.0

Olyset	Permethrin	g/kg	20	17.0 - 23.0	21.0	21.6

Net type	Chemical

PermaNet 3.0	Deltamethrin

Piperonyl butoxide

PermaNet 2.0	Deltamethrin

NetProtect	Deltamethrin

Interceptor	Alpha-cypermethrin

Olyset	Permethrin


Female	Normal weight (BMI 5th to 85th)	P value	Overweight (BMI over 85th)	P value	P value

NW	CONW	OW	COOW

	604 (72.7%)	83 (9.6%)	NW versus CONW	20 (2.5%)	125 (15.1%)	OW versus COOW	Among groups


EE Estimation Models	Static Activities	Dynamic Activities	Average

SI	ST	REST	WK	AS	RU

(1) 	1.11 (0.54	0.94		1.48 	2.3		1.71 (0.68)


Blood products within the first 24 h	Median [IQR]

 Red Blood Cells (Unit)	14 [11–19]

 Fresh Frozen Plasma (Unit)	12 [8–16]

 Platelet (Unit)	2 [1–3]

 Fibrinogen concentrate (gr)	4.5 [3–7.5]

Emergency procedures	N (%)

 Surgery for bleeding	206 (64)

 Embolization	83 (26)


	Assaulted	Not assaulted	P

STAI	101 (89-109)	77 (69-98)	< 0,001

	Assaulted	Not assaulted	P

Anxiety trait	48 (41-55)	40 (38-43)	0,01

Anxiety state	51 (46-59)	39 (34-46)	< 0,001


Parity	Pigs	Rabbits

Litter size	Average BW	Litter size	Average BW

1	0.21	0.29	0.09	0.23


Characteristic	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9

Sex	Male	Female	Female	Female	Female	Female	Female	Male	Female

Age (years)	41	44	36	45	43	51	49	31	37

Medical history

 Palpitations/headaches/sweating/hypertension	Yes	Yes	Yes					Yes

 Other			Type 1 neurofibromatosis		Takotsubo

Blood pressure at admission (mmHg)	160/120	180/108	157/107	130/110	140/100	130/85	141/107	160/100	129/99

Pre-ECMO LVEF (%)	5	20	15	20	30	20	20	30	20

Maximum troponin I (ng/L)	2200	34,000	43,000	15,000	2000	18,000	237	4994	2083

NT pro-BNP at admission (ng/L)			18,363		25,282	6363	18,471		9264

ECMO duration (days)	4	1	6	7	3	3	2	7	4

Urinary metanephrine (N < 340 μg/24 h)	ND	ND	ND	ND	1894	7192	8738	2862	2582

Urinary normetanephrine (N < 440 μg/24 h)	ND	ND	ND	ND	4973	3650	11,910	11,268	9254

Pheochromocytoma size (mm), side	78 × 75 × 70, right	60 mm, left	ND, autopsy	29, left	70, left	103 × 95 × 75, right	57 × 47, right	59 × 38, left	88 × 74×91, left

Characteristic	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9

Age (years)	41	44	36	45	43	51	49	31	37

Medical history

Palpitations/headaches/sweating/hypertension	Yes	Yes	Yes					Yes

Other			Type 1 neurofibromatosis		Takotsubo

Blood pressure at admission (mmHg)	160/120	180/108	157/107	130/110	140/100	130/85	141/107	160/100	129/99

Pre-ECMO LVEF (%)	5	20	15	20	30	20	20	30	20

Maximum troponin I (ng/L)	2200	34,000	43,000	15,000	2000	18,000	237	4994	2083

NT pro-BNP at admission (ng/L)			18,363		25,282	6363	18,471		9264

ECMO duration (days)	4	1	6	7	3	3	2	7	4

Urinary metanephrine (N < 340 μg/24 h)	ND	ND	ND	ND	1894	7192	8738	2862	2582

Urinary normetanephrine (N < 440 μg/24 h)	ND	ND	ND	ND	4973	3650	11,910	11,268	9254

Pheochromocytoma size (mm), side	78 × 75 × 70, right	60 mm, left	ND, autopsy	29, left	70, left	103 × 95 × 75, right	57 × 47, right	59 × 38, left	88 × 74×91, left


 	n	Days with absence from worka	Days with partial absence from workb	Total days affectedc	Percent absence from workd	Excess percent absence from work	FTE*

Mild/No Psychological Distress	2,463	0.6 (0.05)	1.6 (0.14)	1.4 (0.11)	5.0%	Reference	--

Moderate Psychological Distress	414	1.1 (0.10)	2.4 (0.32)	2.2 (0.25)	7.9%	2.9%	18

Severe Psychological Distress	226	2.1 (0.26)	3.1 (0.43)	3.6 (0.36)	12.8%	7.8%	23

Total Excess Absence from Work (FTE)	 	 	 	 	 	 	41


MIGS ID	Property	Term	Evidence codea

		Domain Bacteria	TAS [5]

		Phylum Cyanobacteria	TAS [6-8]

		Class Cyanobacteria	TAS [8,9]

	Current classification	Order Unknown

		Family 1.1	TAS [7]

		Genus Rubidibacter	TAS [1]

		Species Rubidibacter lacunae	TAS [1]

		Type strain KORDI 51-2	TAS [1]

	Gram stain	Not reported

	Cell shape	Rods	TAS [1]

	Motility	None	TAS [1]

	Sporulation	None	IDA

	Temperature range	25-35oC	TAS [1]

	Optimum temperature	30oC	TAS [1]

MIGS-6	Habitat	Seawater	TAS [1]

MIGS-6.3	Salinity	2-7% (optimum: 5)	TAS [1]

MIGS-22	OxygenCarbon sourceEnergy source	AerobicAutotrophPhototroph	TAS [1]TAS [1]TAS [1]

MIGS-15	Biotic relationship	Free living	TAS [1]

MIGS-14	Pathogenicity	None	NAS

MIGS-4	Geographic location	Chuuk state, Micronesia	TAS [1]

MIGS-5	Sample collection time	July, 2004	IDA

MIGS-4.1 	Latitude	7o 13’ N	IDA

MIGS-4.2	Longitude	151o 58’ E	IDA

MIGS-4.3	Depth	40 m	IDA

MIGS-4.4	Altitude	Not applicable	NAS


	Model 1:Demographics	Model 2:ACGs & Demographics	Model 3:ADGs, Sel. EDCs & Demographics	Model 4:2002 Expenditures & Demographics	Model 5:ADGs, Sel. EDCs, 2002 Expenditures & Demographics

2003 Top 0.5% Predicted User

Demographics	0.49%*	0.10%	0.03%	0.03%	0.02%

ACGs & Demographics		0.50%	0.07%	0.08%	0.06%

ADGs, 19 EDCs & Demographics			0.50%	0.19%	0.29%

2002 Expenditures & Demographics				0.50%	0.36%

ADGs, 19 EDCs, 2002 Expenditures & Demographics					0.50%

2003 Top 1% Predicted User

Demographics	1.00%	0.21%	0.11%	0.15%	0.11%

ACGs & Demographics		1.00%	0.30%	0.30%	0.32%

ADGs, 19 EDCs & Demographics			1.00%	0.40%	0.65%

2002 Expenditures & Demographics				1.00%	0.69%

ADGs, 19 EDCs, 2002 Expenditures & Demographics					1.00%

2003 Top 5% Predicted User

Demographics	4.96%*	2.43%	2.09%	2.46%	2.01%

ACGs & Demographics		5.00%	3.43%	3.02%	3.21%

ADGs, 19 EDCs & Demographics			5.00%	3.09%	4.06%

2002 Expenditures & Demographics				5.00%	3.73%

ADGs, 19 EDCs, 2002 Expenditures & Demographics					5.00%

	Model 5:ADGs, Sel. EDCs, 2002 Expenditures & Demographics

ADGs, 19 EDCs, 2002 Expenditures & Demographics	5.00%


	Patient’s results	Reference range

Immunoglobulin levels

 IgM, serum (mg/dL)	30	41–164

 IgA, serum (mg/dL)	68	14–122

 IgE, total (IU/mL)	10	< 60

 IgG, serum (mg/dL)	868	331–1164

Lymphocyte subset panel

 CD4+ lymphocyte (%)	43.3	23–48

 CD4+ lymphocyte count (/μL)	1115.74	500–2400

 CD8+ lymphocyte (%)	30.06	14–33

 CD8+ lymphocyte count (/μL)	788.49	300–1600

 CD 56+ cell (%)	12	4–23

	Patient’s results	Reference range

Immunoglobulin levels

IgM, serum (mg/dL)	30	41–164

IgA, serum (mg/dL)	68	14–122

IgE, total (IU/mL)	10	< 60

IgG, serum (mg/dL)	868	331–1164

Lymphocyte subset panel

CD4+ lymphocyte (%)	43.3	23–48

CD4+ lymphocyte count (/μL)	1115.74	500–2400

CD8+ ly		14


Times until treatment	With complications	Without complications	Total

<24 hours	6	9	15

1-2 days	5	3	8

3–7 days	3	5	8

8–14 days	2	0	2

>15 days	5	2	7

Total 	21	19	40


Technical Characteristic	Value

Measurement range	30 m (indoors)/15 m (outdoors)

Measurement speed	43,200 points/second

Accuracy in the 3D representation	±0.1%

Field of view	270° (H) × 360° (V-in rotation)

Weight of head scanner	1.0 kg


		Estimated vs actual Y

	Missing	15 %	30 %


mAb	Specificity/Reference	WT	vti13	prp3	prp3/vti13	csld2	csld3-2	xxt1	xxt2	xxt5

PECTINS

JIM7	High DE HG[31]	-	-	-	-	-	NA	-	-	-

LM19	Low DE HG[23]	++	++	+	++	-	NA	+	+	+

LM5	(1–4)-galactan[32]	-	-	-	-	-	NA	-	-	-

LM6	(1–5)-arabinan[33]	-	-	-	-	-	NA	-	-	-

INRA-RU1	Rhamnogalacturonan-I[34]	-	-	-	-	-	NA	-	-	-

XYLOGLUCAN

LM15	xylosylated XyG[29]	++	-	++	++	+	NA	-	-	-

LM25	galactosylated XyG epitope[20]	++	-	+	++	+	NA	-	-	-

MANNAN

BS-400-4	ß(1–4)-mannan/galacto-ß(1–4)-mannan[35]	-	-	-	-	-	NA	-	-	-

XYLAN

LM10	(1–4)-xylan[36]	++	-	++	++	++	NA	-	++	++

LM11	ß(1–4)-xylan/arabinoxylan[36]	+	-	+	+	-	NA	-	-	-

AGP

LM2	AGP[37]	-	-	-	-	-	NA	-	-	-

JIM13	AGP[38]	+	+	+	+	+	NA	+	+	+

JIM8	AGP[39]	+	+	+	+	+	NA	+	+	-

EXTENSIN

LM1	Extensin[40]	++	++	+	++	+	NA	+	+	+

JIM20	Extensin[41]	+	+	+	+	+	NA	+	+	+

mAb	Specificity/Reference	WT	vti13	prp3	prp3/vti13	csld2	csld3-2	xxt1	xxt2	xxt5

LM25	galactosylated XyG epitope[20]	++	-	+	++	+	NA	-	-	-

MANNAN

BS-400-4	ß(1–4)-mannan/galacto-ß(1–4)-mannan[35]	-	-	-	-	-	NA	-	-	-

XYLAN

LM10	(1–4)-xylan[36]	++	-	++	++	++	NA	-	++	++

LM11	ß(1–4)-xylan/arabinoxylan[36]	+	-	+	+	-	NA	-	-	-

AGP

LM2	AGP[37]	-	-	-	-	-	NA	-	-	-

JIM13	AGP[38]	+	+	+	+	+	NA	+	+	+

JIM8	AGP[39]	+	+	+	+	+	NA	+	+	-

EXTENSIN

LM1	Extensin[40]	++	++	+	++	+	NA	+	+	+

JIM20	Extensin[41]	+	+	+	+	+	NA	+	+	+


Variable	Students (n = 22)	Academics (n = 10)	Alumni (n = 74)

M	SD	M	SD	M	SD

MAKSS Awa	2.5	4.3	2.58	3.2	2.62	4.

Variable	Students (n = 22)	Academics (n = 10)	Alumni (n = 74)

M	SD	M	SD	M	SD

reness	3	9		7		06

MAKSS Knowledge	2.44	5.11	2.36	6.23	2.57	5.54

MAKSS Skills	2.58	6.82	2.40	6.06	2.70	7.20

MCSDS Social Desirability	0.46	2.62	0.56	3.23	0.52	3.10


	NS-TOPSAR	Sentinel-1	Airborne

	IW Mode	EW Mode	TOPSAR in [24]

Carrier frequency (GHz)	9	5.405	5.405	9.65

Altitude (km)	25	693	693	5

Resolution	4.5 × 4.5	5 × 20	20 × 40	2 × 1

(range × azimuth, m)

Swathwidth (km)	100	250	400	20

Revisit time	several hours	6 days	6 days	within one hour

Endurance	up to a few years	tens of years	tens of years	up to a few days


Variable	Univariate analysis	Multivariate analysis

	OR (95% CI)	P value	OR (95% CI)	P value

Severity of CoA(severe)	4.93 (1.33–18.31)	0.017	7.46 (1.19–46.76)	0.032


Variable	No. of patients (%)

Age, years (mean ± SD)	64.7 ± 13.7

Gender, male	24 (77.4)

Current/ex-smoker	15 (48.4)

Underlying disease	30 (96.8)

 DM	18 (58.1)

 Chronic lung disease	12 (38.7)

COPD/asthma	8 (25.8)

Old TB	2 (6.5)

Bronchiectasis	2 (6.5)

 Solid organ cancer	4 (12.9)

 Hematologic disease	4 (12.9)

 Liver cirrhosis	3 (9.7)

Systemic steroids before diagnosis	17 (54.8)

 Duration of steroids before ICU admission, day, median (IQR)	49 (14–90)

 Daily dosage of steroids, mg, median (IQR)	50 (29–71)

Inhaled corticosteroids before diagnosis	3 (9.7)

H1N1 infection before diagnosis	3 (9.7)

Variable	No. of patients (%)

Bronchiectasis	2 (6.5)

Solid organ cancer	4 (12.9)

Hematologic disease	4 (12.9)

Liver cirrhosis	3 (9.7)

Systemic steroids before diagnosis	17 (54.8)

Duration of steroids before ICU admission, day, median (IQR)	49 (14–90)

Daily dosage of steroids, mg, median (IQR)	50 (29–71)

Inhaled corticosteroids before diagnosis	3 (9.7)

H1N1 infection before diagnosis	3 (9.7)


Male ID	Approximate time between death and necropsy (hours)	Whole RNA concentration (ng/μl)


Codon position (HXB2 gp41)	Selection analysis method	Detected elsewherea

	SLAC	FEL	IFEL

24		B, D	B, D	T, C

54		B, F, CRF 02_AG	CRF 01_AE

96	C, D	C, A, D	C, B, D, CRF 01_AE	T

101	B, G	B, G	B, G

130	B	C, A, B	C, B	T

137	A, B	A, B, G	B	T

163	C, D, CRF 02_AG	C	C, D, CRF 02_AG	C

165	D, G		C, A, G

172		C, B, G, CRF 02 _AG

210	C, A, CRF 01_AE	C, A, B, D, F, G	C, D, CRF 01_AE

214b	A	A, B	A, B

221	G, CRF 01_AE	C, A, G, CRF 01_AE, CRF 02_AG	C, D, G, CRF 01_AE

230		A, D	A, G, CRF 01_AE

271		C, CRF 01_AE	C, B, D

328	C, B, G	C, B, G	C, B, G

332	A, B, G	A, B, G	B, D, G, CRF 01_AE	C

349		C, F, CRF 01_AE, CRF 02_AG	CRF 02_AG	C


	Study population	Time (number) of survey	Survey population	No. examined (%)	Mean age years	No. positive (%)	GMI* for all examined

Community surveys	Kirare	Nov-11 (8)	178	120 (67.4)	10.1	33 (27.5)	0.3384


Strain	Selected on:	Resistant to:

KWAG-base	No selection	-

KWAG-perm	Permethrin (0.75%)	Permethrin

MBN-base	No selection	DDT (low-level)

MBN-DDT	DDT (4%)	DDT, deltamethrin and permethrin (cross-resistance)

Strain

KWAG-base

KWAG-perm

MBN-base

MBN-DDT

Selected on:	Resistant to:

No selection	-

Permethrin (0.75%)	Permethrin

No selection	DDT (low-level)

DDT (4%)	DDT, deltamethrin and permethrin (cross-resistance)


 	Adult patients	Elderly patients	P-value

Healthy donors, number	14	16

Age, y, mean ± SD	24.0 ± 8.1	78.4 ± 8.2	<0.001

Male, n (%)	11 (79)	11 (69)	0.45

Comorbidity, n (%)	0 (0)	5 (31)	0.30

Severe sepsis, number of patients	15	40

Age, y, mean ± SD	34.8 ± 11.9	77.6 ± 7.1	<0.001

Male, n (%)	12 (80)	28 (70)	0.45

Septic shock, n (%)	5 (33)	18 (45)	0.43

Ventilator rate, n (%)	11 (73)	31 (78)	0.75

APACHE II score, mean ± SD	19.2 ± 6.9	22.5 ± 6.9	0.14

 APACHE II-age score, mean ± SD	19.0 ± 5.0	15.8 ± 7.6	0.08

SAPS II score, mean ± SD	46.6 ± 17.5	58.6 ± 16.1	0.10

 SAPS II-age score, mean ± SD	43.3 ± 9.6	42.7 ± 11.6	0.17

SOFA score, mean ± SD	7.4 ± 4.6	7.3 ± 4.1	0.87

Comorbidity, n (%)	4 (27)	31 (78)	0.01

Types of bacteria detected in first 72 h, n (%)

 Gram-positive bacteria	8 (53)	22 (55)	0.91

 Gram-negative bacteria	15 (100)	40 (100)	1.00

 Fungi	6 (40)	17 (43)	0.87

Treatment, n (%)

Adjunctive hydrocortisone, n (%)	1 (7)	2 (5)	0.81

Organ support types

Ventilator, n (%)	12 (80)	35 (86)	0.48

Hemofiltration, n (%)	3 (20)	10 (25)	0.70

Organ support duration

Ventilator, d, mean ± SD	11.6 ± 12.3	9.3 ± 16.1	0.68

Hemofiltration, d, mean ± SD	7.3 ± 6.6	9.9 ± 12.8	0.26

ICU stay, d, mean ± SD	21.9 ± 22.6	16.6 ± 16.1	0.57

ICU-free days in 28 days, d, mean ± SD	11.6 ± 9.6	10.9 ± 11.6	0.64

Hospital stay, d, mean ± SD	36.3 ± 35.9	39.6 ± 41.9	0.41

	Adult patients	Elderly patients	P-value

Organ support types

Ventilator, n (%)	12 (80)	35 (86)	0.48

Hemofiltration, n (%)	3 (20)	10 (25)	0.70

Organ support duration

Ventilator, d, mean ± SD	11.6 ± 12.3	9.3 ± 16.1	0.68

Hemofiltration, d, mean ± SD	7.3 ± 6.6	9.9 ± 12.8	0.26

ICU stay, d, mean ± SD	21.9 ± 22.6	16.6 ± 16.1	0.57

ICU-free days in 28 days, d, mean ± SD	11.6 ± 9.6	10.9 ± 11.6	0.64

Hospital stay, d, mean ± SD	36.3 ± 35.9	39.6 ± 41.9	0.41


In vitroresponse to:		ControlsN (%)	TST+, suspected LTBIN (%)	Cured TBN (%)

		13 (100)	106 (100)	29 (100)

QFT-IT

	Positive N.(%)	0	70 (66.03)	19 (63.3)

	IFN-γ (IU/ml) median (IQR)Among all	0 (0-0.1)	2.3 (0-15.1)	1.1 (0.1-4.2)

	IFN-γ (IU/ml) median (IQR)Among the positive responders	NA	8.1 (2.4-22.6)	3.8 (1.5-5.0)

RD1 proteins

	Positive N.(%)	0	64 (60.3)	19 (65.5)

	IFN-γ (IU/ml) median (IQR)Among all	0 (0-0.2)	1.4 (0.2-8.9)	1.6 (0.4-2.9)

	IFN-γ (IU/ml) median (IQR)Among the positive responders	NA	7.6 (2.3-20.3)	2.6 (1.6-6.2)

In vitroresponse to:		ControlsN (%)	TST+, suspected LTBIN (%)	Cured TBN (%)

		13 (100)	106 (100)	29 (100)

	Positive N.(%)	0	70 (66.03)	19 (63.3)

	IFN-γ (IU/ml) median (IQR)Among all	0 (0-0.1)	2.3 (0-15.1)	1.1 (0.1-4.2)

	IFN-γ (IU/ml) median (IQR)Among the positive responders	NA	8.1 (2.4-22.6)	3.8 (1.5-5.0)

RD1 proteins

	Positive N.(%)	0	64 (60.3)	19 (65.5)

	IFN-γ (IU/ml) median (IQR)Among all	0 (0-0.2)	1.4 (0.2-8.9)	1.6 (0.4-2.9)

	IFN-γ (IU/ml) median (IQR)Among the positive responders	NA	7.6 (2.3-20.3)	2.6 (1.6-6.2)


Unit*	Color¶	Day†	Positive culture‡	Leakage§

1	Red	None	No	No

2	Yellow/orange	30	Yes	Yes§

3	Yellow	9	Yes	Yes§

4	Red	None	No	No

5	Yellow/orange	19	Yes	Yes§

6	Orange	15	Yes	Yes§

7	Red	None	No	No

8	Orange	25	No	No

9	Red	None	No	No

10	Yellow	4	Yes	Yes§

11	Red	None	No	No

12	Red	None	No	No

13	Yellow	4	Yes	Yes§

14	Red	None	No	No

15	Yellow	13	No	Yes§

16	Orange	26	No	No

17	Orange	15	No	No

18	Red	None	No	No

19	Orange	30	No	No

20	Yellow	18	No	Yes§


Study population characteristics	mean (SD)

Gestational age (weeks)	32.5 (2.1)

Weight (g)	1700 (401)

Length (cm)	41.1 (3.3)

Head circumference (cm)	29.9 (1.6)

Apgar score at 1 minute	8 (1)

Apgar score at 5 minutes	9 (1)

Study population characteristics	mean (SD)

Gestational age (weeks)	32.5 (2.1)

Weight (g)	1700 (401)

Length (cm)	41.1 (3.3)

Head circumf	2

Study population characteristics	mean (SD)

erence (cm)	9.9 (1.6)

Apgar score at 1 minute	8 (1)

Apgar score at 5 minutes	9 (1)


Structure identifier	Description	No. of models	Reference(s)

U_1D3Z	Solution NMR ensemble	10	[35]

U_COCO	Solution NMR ensemble (1D3Z.pdb) plus COCO-derived conformers	20	this study

U_1XQQ	DER ensemble	128	[14]

U_2NR2	MUMO ensemble	144	[15]

U_2K39	EROS ensemble	116	[10]

U_ISD	ISD ensemble(ensemble provided as an example with the ISD 1.1 package)	25	[26]

U_NNR	NOE(2)+S2(8)+RDC(8) restrained ensemble	32	this study

U_CNS	RECOORD ensemble calculated with CNS	25	[34]

U_CNW	RECOORD ensemble calculated with CNS in water	25	[34]

U_CYA	RECOORD ensemble calculated with CYANA	25	[34]

U_CYW	RECOORD ensemble calculated with CYANA in water	25	[34]

U_1UBQMD	5ns MD simulation started from the X-ray structure 1UBQ	32	this study

U_1G6J	Ubiquitin in reverse micelles	32	[36]

U_1V80	Ubiquitin at 30 bar	10	[37]

U_1V81	Ubiquitin at 3000 bar	10	[37]

U_2JZZ	Solid-state NMR structure	20	[38]

Structure identifier	Description	No. of models	Reference(s)

U_1G6J	Ubiquitin in reverse micelles	32	[36]

U_1V80	Ubiquitin at 30 bar	10	[37]

U_1V81	Ubiquitin at 3000 bar	10	[37]

U_2JZZ	Solid-state NMR structure	20	[38]


Variables	Fragmented QRS(n = 79)

Age,years	51.4 ± 4.6

Gender, Male,%	59.5

Hypertension,%	30.4

Smoking,%	38

CAD,%	41.8

MVD,%	25.3

Stenotic CAD,%	40.5

LDL,mg/dl	125 ± 34

TG,mg/dl	161 ± 43

HDL,mg/dl	39.1 ± 8.2

Glucose	91 ± 14

Creatinin	0.95 ± 0.25

WBC	6.9 ± 2.3

Hemoglobin	13 ± 2.3

LVEF	59.3 ± 6


Patient no.	Underlying disease	CSF WBC (cells/mm3)	Imaging pattern (MRI)	CSF HSV viral load (copies/ml)	Outcome

1	Normal	230	Fronto-temporal lesions	16,975	Complete recovery

2	Normal	350	Fronto-temporal lesions	2214	Complete recovery

3	Normal	70	Fronto-temporal lesions	Qualitative PCR	Complete recovery

4	Normal	730	Temporal lobe lesions	11,755,813	Partial recovery

5	Normal	22	Fronto-temporal and thalamic lesions	500,000	Partial recovery

6	Normal	90	Temporal lobe lesions	71,875	Complete recovery

7	Hematologic malignancy	147	Temporal lobe lesions	30,750	Complete recovery

8	Normal	75	Fronto-temporal and thalamic lesions	12,200	Partial recovery

9	DM	510	Other cortical and subcortical lesions	3325	Dead

10	Normal	40	Normal CT	1491	Partial recovery

11	Hematologic Malignancy	40	Other cortical and subcortical lesions	740	Dead

12	Normal	60	Fronto-temporal and thalamic lesions	39	Partial recovery

13	DM	15	N/A	Qualitative PCR	Partial recovery

14	Normal	600	Temporal lobe lesions	Qualitative PCR	Partial recovery

15	Old ischemic stroke	22	Fronto-temporal lesions	Qualitative PCR	Partial recovery

16	Normal	30	Temporal lobe lesions	Qualitative PCR	Partial recovery

17	Normal	20	Other cortical and subcortical lesions	Qualitative PCR	Partial recovery


Variable	Non-smoker (n = 22)	Smoker (n = 22)	t-test

 	Mean	SD	Mean	SD	t-value	P-value

Age (years)	41.5	15.8	46.0	11.4	1.1	.290

Duration of smoking (years)	NA	NA	24.3	9.7	NA	NA

Number of cigarettes smoked daily	NA	NA	17.4	7.0	NA	NA

Brinkman index	NA	NA	430	246.7	NA	NA


Pathogenic step	Candidate biomarkers	Potential approaches and targets of disease-specific therapy

Elevated production of Gd-IgA1	Serum level of Gd-IgA1 (lectin or antibody ELISA)IgA1 hinge-region O-glycopeptide profiles (mass spectrometric analysis)	Reduce production of Gd-IgA1Manipulate enzyme expression in IgA1-producing cellsReduce number of cells secreting Gd-IgA1

Production of autoantibodies specific for Gd-IgA1	Serum levels of autoantibodies (IgG and IgA) specific for Gd-IgA1	Reduce production of autoantibodies specific for Gd-IgA1Deplete cells producing the autoantibodyManipulate affinity maturation of autoantibodies to reduce affinity for the autoantigenRemove the autoantibodies from circulation

Formation of pathogenic IgA1-containing immune complexes	Circulating IgA-containing immune complexesSpecific components of circulating immune complexes	Block immune complex formation and enhance their removal from circulation and catabolismBlock epitopes of autoantigen (Gd-IgA1) by non-crosslinking antibodiesBlock autoantibodies by an epitope-containing glycopeptide or glycomimeticBlock activation of complement

Glomerular deposition and injury	Complement components and their degradation productsNovel markers of glomerular injuryUrinary immune complexesUrinary peptidomic profiles	Block activation of mesangial cellsReduce complement activation in situBlock binding of IgA1-containing immune complexes to mesangial cellsBlock mesangial-cell signaling induced by IgA1-containing immune complexes


Brain region intensity	MNI peak coordinates (X, Y, Z)	Volume	Peak activity

Precuneus	3	−69	57	120	9.2972

Posterior cingulate gyrus	0	−66	12	63	6.3883

Right medial superior frontal gyrus	3	63	9	67	6.6306

Left middle frontal gyrus	−12	33	51	30	6.0696

Left medial superior frontal gyrus	−3	30	57	74	6.6797

Left supplementary motor area	−3	15	69	52	5.598

Brain region intensity	MNI peak coordinates (X, Y, Z)	Volume	Peak activity

Left supplementary motor area	−3	15	69	52	5.598


Demographic data	Households

Number of household members	N	%

1–4 members	29	26.9%

5–8 members	32	29.6%

9–12 members	34	31.5%

>13 members	13	12.0%

Total	108	100.0%

Mean household size (members)	8.6

Median household size (members)	8

Number of children <5 in households	N	%

0 children	9	8.3%

1 children	16	14.8%

2 children	34	31.5%

3 children	29	26.9%

4 children	10	9.3%

5 children	3	2.8%

6 children	5	4.6%

≥10 children	2	1.8

Total	97	100.0

Mean number of children <5 per household	2.6

Median number of children <5 per household	2

Profession of head of household	N	%

Subsistence farmer	46	42.6%

Subsistence farmer + Daily worker	8	7.4%

Subsistence farmer + Other profession*	6	5.6%

Subsistence farmer + Farmer for trading	5	4.6%

Health worker	5	4.6%

No work	5	4.6%

Workman	4	3.7%

Subsistence farmer + Hunter	4	3.7%

Subsistence farmer + Teacher	3	2.8%

Subsistence farmers + Other professions†	14	13.0%

Other professions‡	7	6.5%

Missing	1	0.9%

Total	108	100.0%

Demographic data	Households

Number of household members	N	%

1–4 members	29	26.9%

5–8 me	32	29.6

mbers		%

9–12 members	34	31.5%

>13 members	13	12.0%

Total	108	100.0%

Mean household size (members)	8.6

Median household size (members)	8

Number of children <5 in households	N	%

0 children	9	8.3%

1 children	16	14.8%

2 children	34	31.5%

3 children	29	26.9%

4 children	10	9.3%

5 children	3	2.8%

6 children	5	4.6%

≥10 children	2	1.8

Total	97	100.0

Mean number of children <5 per household	2.6

Median number of children <5 per household	2

Profession of head of household	N	%

Subsistence farmer	46	42.6%

Subsistence farmer + Daily worker	8	7.4%

Subsistence farmer + Other profession*	6	5.6%

Subsistence farmer + Farmer for trading	5	4.6%

Health worker	5	4.6%

No work	5	4.6%

Workman	4	3.7%

Subsistence farmer + Hunter	4	3.7%

Subsistence farmer + Teacher	3	2.8%

Subsistence farmers + Other professions†	14	13.0%

Other professions‡	7	6.5%

Missing	1	0.9%

Total	108	100.0%


	HIV-infected	Healthy controls

LTNP	Normal progressors

Number	5	13	7

Median age, years	49	39	41

Median CD4 cells, cells/μl	1240	565	n.a.

Median Log (viral load)	1.7	4.3	n.a.


Year of birth	Number of ONS Birth records	Number of ONS birth records linked to HES birth records	Percentage linked

2005	617 613	609 778	98.73


Model	Covariates included	OR (95% CI)*	Pvalue

1	Long PPI exposure (2 or more days)	2.19 (1.27 – 3.78)	.005

H2RA use	1.12 (0.70 – 1.79)	.628

Antibiotic use	2.53 (1.23 – 5.23)	.012

Immunosuppression	0.79 (0.51 – 1.23)	.297

2	Long PPI exposure (2 or more days)	2.08 (1.26 – 3.43)	.004

Antibiotic use	2.53 (1.25 – 5.29)	.010

Immunosuppression	0.79 (0.51 – 1.22)	.282

3	Long PPI exposure (2 or more days)	2.03 (1.23 – 3.36)	.006

Antibiotic use	2.52 (1.23 – 5.18)	.012

Covariates included	OR (95% CI)*	Pvalue

Long PPI exposure (2 or more days)	2.19 (1.27 – 3.78)	.005

H2RA use	1.12 (0.70 – 1.79)	.628

Antibiotic use	2.53 (1.23 – 5.23)	.012

Immunosuppression	0.79 (0.51 – 1.23)	.297

Long PPI exposure (2 or more days)	2.08 (1.26 – 3.43)	.004

Antibiotic use	2.53 (1.25 – 5.29)	.010

Immunosuppression	0.79 (0.51 – 1.22)	.282

Long PPI exposure (2 or more days)	2.03 (1.23 – 3.36)	.006

Antibiotic use	2.52 (1.23 – 5.18)	.012


	MBA failures	MBA controls	p-Value

Transportal ACLR (n = 26)	25.0	20.7	<0.001

Transtibial ACLR (n = 28)	24.0	20.3	0.003


Variable	SHAM	STZ

Aortic flow rate (mL g-1 min-1)	24.4 ± 1.5	14.2 ± 2.9*

Coronary flow rate (mL g-1 min-1)	6.05 ± 0.39	7.16 ± 0.65

Work (J kg-1)	1.48 ± 0.09	1.06 ± 0.11*

Variable	SHAM	STZ

Total Vo2 (J kg-1)	10.4 ± 0.51	10.0 ± 0.66

Total efficiency (%)	14.5 ± 0.49	10.4 ± 0.88*


Factor	Respondents(n = 56)

Comorbidities of parturient	31 (55)

BMI	39 (70)

Quality of SAD seal	42 (75)

Fasting status 	24 (43)

Other

 Team skill	2 (4)

 Clinical situation	2 (4)

 Speed of surgeon	2 (4)

Factor	Respondents(n = 56)

Comorbidities of parturient	31 (55)

BMI	39 (70)

Quality of SAD seal	42 (75)

Fasting status	24 (43)

Other

Team skill	2 (4)

Clinical situation	2 (4)

Speed 	2 (4

Factor	Respondents(n = 56)

of surgeon	)


Health behaviour	Amount or frequency	Girls	Boys

		Latent class I n = 1256	Latent class II n = 1071	Latent class III n = 1098	Latent class I n = 862	Latent class II n = 628	Latent class III n = 1583

Stress-related eating	At least to some extent	732 (58.3%)	527 (49.2%)	218 (19.9%)	188 (21.8%)	142 (22.6%)	136 (8.6%)

Physical activity	<2 hours a week	310 (24.7%)	694 (64.8%)	384 (35.0%)	126 (14.6%)	361 (57.5%)	471 (29.8%)


Genes	Forward primer(5′‐ 3′)	Reverse primer(5′‐ 3′)

GAPDH	CGCTAACATCAAATGGGGTG	TTGCTGACAATCTTGAGGGAG

HIF‐1α	AAGCCCAGAGTCACTGGGACT	GTACTCACTGGGACTGTTAGGCTC

BMP‐2	GAAGCCATCGAGGAACTTTCAG	GGAAATTTTGAGCTGGCTGTG

Runx2	ACTCTGCCGAGCTACGAAATG	GGGACCGTCCACTGTCACT

COL‐I	CCGTGACCTCAAGATGTGCC	GAACCTTCGCTTCCATACTCG

OST	GATGCGGTCCCTAGTTCTACC	CCTCCAGTGAGTGGGATGTTT

OPN	AGCACACAAGCAGACGTTTTG	GCAACTGGGATGACCTTGATAG

ERK1	CTGGCTTTCTGACCGAGTATGT	AATTTAGGTCCTCTTGGGATGG

ERK2	GCACCAACCATTGAGCAGAT	TCACGGTGCAGAACATTAGCT

p38	AGATGCCGAAGATGAACTTCG	GGTCAGGCTCTTCCATTCGT

JNK	TCCAGCACCCGTACATCAAC	TCTTAGTTCGCTCCTCCAAATC


Participant (diagnosis)	Trauma type	Psychotic symptoms	Target hotspot and associated memory	Key tf-CBTp; phase 4 intervention

P1Primary: unspecified non-organic psychosisSecondary: PTSD	Childhood; multipleSought asylum in the UK	Auditory command hallucinationsVisual hallucinationsParanoia	Witnessing murder of childhood friend; childhood physical abuse; held captive and tortured	Cognitive restructuringReliving with CRImagery rescripting (for nightmares and visions)

P2Primary: schizophreniaSecondary: severe depressive episode with psychotic symptoms	Adult; single event	Auditory command hallucinationsPersecutory beliefs	Living in conflict zone and held at gunpoint by terrorists	Cognitive restructuringReliving with CR

P3Primary: other non-organic psychotic disorderSecondary: PTSD	Childhood; multipleSought asylum in the UK	Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs	Living in conflict zone (civil war/genocide); parents killed. Held captive and gang raped; witnessed murder of grandfather	Cognitive restructuringImagery rescripting

P4Primary: unspecified non-organic psychosisSecondary: none	Childhood; single event	Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs	Rape in childhood	Cognitive restructuringImagery rescripting for trauma event and visual hallucinationsSchema work

P5Primary: PTSDSecondary: emotionally unstable personality disorder	Adult; multiple	Auditory command hallucinationsVisual, olfactory, and tactile hallucinationsPersecutory beliefs	Several rapes and extreme physical assaults (long-term domestic violence); stillbirth of child	Cognitive restructuringReliving with CR for trauma eventsImagery rescripting for visual, olfactory tactile, and hallucinations

P6Primary: severe depressive episode with psychotic symptomsSecondary: none	Childhood; single event	Auditory hallucinationsPersecutory beliefs	Physical and emotional abuse	Imagery rescriptingSchema work

P7Primary: schizophreniaSecondary: severe depressive episode with psychotic symptoms	Adult; single event	Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs	Being threatened with a knife	Cognitive restructuring reliving with CR

P8Primary:PTSDSecondary: severe depressive episode with psychotic symptoms	Adult; multipleSought asylum in the UK	Commanding voicesVisual and tactile hallucinationsPersecutory beliefs	Long-term imprisonment with physical and sexual torture. Witnessing murder in prison	Cognitive restructuring reliving with CRImagery rescripting

P9Primary: severe depressive episode with psychotic symptomsSecondary: none	Childhood; multiple	Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs	Repeated childhood physical abuse	Cognitive restructuringImagery rescripting for trauma events, visual and tactile hallucinations, and nightmares

Participant (diagnosis)	Trauma type	Psychotic symptoms	Target hotspot and associated memory	Key tf-CBTp; phase 4 intervention

P8Primary:PTSDSecondary: severe depressive episode with psychotic symptoms	Adult; multipleSought asylum in the UK	Commanding voicesVisual and tactile hallucinationsPersecutory beliefs	Long-term imprisonment with physical and sexual torture. Witnessing murder in prison	Cognitive restructuring reliving with CRImagery rescripting

P9Primary: severe depressive episode with psychotic symptomsSecondary: none	Childhood; multiple	Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs	Repeated childhood physical abuse	Cognitive restructuringImagery rescripting for trauma events, visual and tactile hallucinations, and nightmares


Complain	n of cases	n of positive cases

Discharge	750	20 (2.7%)

Discharge and itching	120	10 (8.3%)

Discharge, itching and burning sensation	130	20 (15.4%)

Total	1000	50

P value	0.129

Complain	n of cases

Discharge	750

Discharge and itching	120

Discharge, itching and burning sensation	130

Total	1000

P value	0.129


Pancreatitis	Neoplastic conditions	Other

Acute	34.4 %	pancreatic ACC	19.8 %	fistula	2.3 %

Chronic	15.3 %	n. r.	9.9 %	transplant rejection	1.5 %

		NEC	4.6 %

		adeno-carcinoma	3.8 %	anastomotic leakage	0.8 %

		IPMN	3.1 %

		other	4.6 %

Total	49.6 %	total	45.8 %	total	4.6 %

Pancreatitis	Neoplastic conditions	Other

Acute	34.4 %	pancreatic ACC	19.8 %	fistula	2.3 %

Chronic	15.3 %	n. r.	9.9 %	transplant rejection	1.5

			4.6

Pancreatitis	Neoplastic conditions	Other

		NEC	%		 %

		adeno-carcinoma	3.8 %	anastomotic leakage	0.8 %

		IPMN	3.1 %

		other	4.6 %

Total	49.6 %	total	45.8 %	total	4.6 %


Test variable	Schizophrenia patients (24)	Healthy adults (24)

	M	SD	M	SD

Age	42.43	6.85	40.63	6.66

Education (in years)	10.5	3.41	11.08	2.78

Digit span forward	4.58	1.31	5.00	1.59

Digit span backward	4.08	1.38	4.88	1.73

PANAS pos	29.05	4.90	31.25	3.23

PANAS neg	18.95	4.25	22.29	6.67

BPRS

Total	22.56	3.14

Positive symptoms	7.31	1.67

Negative symptoms	3.56	1.80

Test variable	Schizophrenia patients (24)	Healthy adults (24)

	M	SD	M

Age	42.43	6.85	40.63

Education (in years)	10.5	3.41	11.08

Digit span forward	4.58	1.31	5.00

Digit span backward	4.08	1.38	4.88

PANAS pos	29.05	4.90	31.25

PANAS neg	18.95	4.25	22.29

BPRS

Total	22.56	3.14

Positive symptoms	7.31	1.67

Negative symptoms	3.56	1.80


Gene	Forward	Reverse

18s rRNA	CCCAGTGAGAATGCCCTCTA	TGGCTGAGCAAGGTGTTATG

Scleraxis	CCCAAACAGATCTGCACCTT	ATCCGCCTCTAACTCCGAAT

Tenascin-C	AACCCGTCCAAAGAGACCTT	GCGTGGGATGGAAGTATCAT

Tenomodulin	GTCCCTCAAGTGAAGGTGGA	CCTCGACGGCAGTAAATACAA

Collagen type-1 alpha 1	TGCGAAGACACCAAGAACTG	GACTCCTGTGGTTTGGTCGT

Cartilage oligomeric matrix protein	AGAACATCATCTGGGCCAAC	CGCTGGATCTCGTAGTCCTC

Thrombos pondin-4	GGGAAATGGGGTTACCTGTT	CGGGTAGCAGGGATGATATT

Gene

18s rRNA

Scleraxis

Tenascin-C

Tenomodulin

Collagen type-1 alpha 1

Cartilage oligomeric matrix protein

Thrombos pondin-4

Forward	Reverse

CCCAGTGAGAATGCCCTCTA	TGGCTGAGCAAGGTGTTATG

CCCAAACAGATCTGCACCTT	ATCCGCCTCTAACTCCGAAT

AACCCGTCCAAAGAGACCTT	GCGTGGGATGGAAGTATCAT

GTCCCTCAAGTGAAGGTGGA	CCTCGACGGCAGTAAATACAA

TGCGAAGACACCAAGAACTG	GACTCCTGTGGTTTGGTCGT

AGAACATCATCTGGGCCAAC	CGCTGGATCTCGTAGTCCTC

GGGAAATGGGGTTACCTGTT	CGGGTAGCAGGGATGATATT


	Level of guidance	Nature of guidance	Health Technology

Meta regression findings	Number of sessions not related to outcome	Better outcomes where guidance provided, and where based on CBT	No differences between technologies (email, telephone, face to face)

Meta synthesis findings	No relevant findings	No relevant findings	No relevant findings

Consensus exercise	Agreement on timing, duration, and number of sessions	Agreement that patient preference should determine the nature of guidance	Agreement that health technology should be accessible, and help with literacy problems.

Incorporated into the intervention	3–10 sessions, 15–30 minutes duration over 5–12 weeks	CBT based. Patient preference delivery of guidance	Devised a self-help manual and also a CD

	Who should deliver guided self-help	Personal experience of depression	Ambivalent help seeking and covert presentation of problems

Meta regression findings	No differences in outcome between professional and paraprofessionals	No relevant findings	No relevant findings

Meta synthesis findings	No relevant findings	Personal experience characterised by feeling of inability to cope, and disturbances to functioning. Use of lay language/metaphors important	Point in illness trajectory where people make service contact, and their prior contact with other help may determine acceptability

Consensus exercise	Most frequent were nurses and primary care graduate workers. Specific training needed	Mixed response to inclusion of lay language and metaphors. Agreement on importance of social functioning, and relapse prevention	None relevant

Incorporated into the intervention	Primary care graduate workers or other mental health professionals	Emphasised return of social functioning. Lay language, metaphors and causal explanations included. Relapse prevention incorporated	Expectations and prior contact emphasised and included in the intervention. Choices and patient preference for interventions included

	Control and helplessness in engaging with treatment	Stigma associated with treatment	Patients' understanding of self-help

Meta regression findings	No relevant findings	No relevant findings	No relevant findings

Meta synthesis findings	Patients reported coping strategies such as distraction, or the use of locations associated with feelings of safety and control	Extent to which guided self-help acknowledges issues of stigma likely to determine acceptability	Seeing the self as the agent of change may be very important

Consensus exercise	Mixed response but emphasis on collaborative working, patient centred goals, and roles i.e. patient as change agent	None relevant	Agreement of collaborative working, explicitly detail roles of both patient and MHW i.e. patient as change agent, coach as facilitator

Incorporated into the intervention	Highlighting intervention as a method of regaining control and incorporating use of coping strategies termed 'respite' in the intervention	Discussed guided self-help as requiring a sense of acting on the world and enhancing self-worth	Explicit team rationale, with the patient as 'team captain', facilitator renamed as 'self-help coach'

	Level of guidance	Nature of guidance	Health Technology

Meta synthesis findings	No relevant findings	Personal experience characterised by feeling of inability to cope, and disturbances to functioning. Use of lay language/metaphors important	Point in illness trajectory where people make service contact, and their prior contact with other help may determine acceptability

Consensus exercise	Most frequent were nurses and primary care graduate workers. Specific training needed	Mixed response to inclusion of lay language and metaphors. Agreement on importance of social functioning, and relapse prevention	None relevant

Incorporated into the intervention	Primary care graduate workers or other mental health professionals	Emphasised return of social functioning. Lay language, metaphors and causal explanations included. Relapse prevention incorporated	Expectations and prior contact emphasised and included in the intervention. Choices and patient preference for interventions included

	Control and helplessness in engaging with treatment	Stigma associated with treatment	Patients' understanding of self-help

Meta regression findings	No relevant findings	No relevant findings	No relevant findings

Meta synthesis findings	Patients reported coping strategies such as distraction, or the use of locations associated with feelings of safety and control	Extent to which guided self-help acknowledges issues of stigma likely to determine acceptability	Seeing the self as the agent of change may be very important

Consensus exercise	Mixed response but emphasis on collaborative working, patient centred goals, and roles i.e. patient as change agent	None relevant	Agreement of collaborative working, explicitly detail roles of both patient and MHW i.e. patient as change agent, coach as facilitator

Incorporated into the intervention	Highlighting intervention as a method of regaining control and incorporating use of coping strategies termed 'respite' in the intervention	Discussed guided self-help as requiring a sense of acting on the world and enhancing self-worth	Explicit team rationale, with the patient as 'team captain', facilitator renamed as 'self-help coach'


Strain	Acetate	Formate	Succinate	Ethanol	Carbon Recovery (%)


Variable		Range

Sex, M/F	33/41

Age, years	63.5 ± 1.1	38–78

BMI, kg/m2	23.0 ± 4.0	13.7–35.3

Smoking status, ever/never	31/43

CTD

RA/SSc/PMDM/SjS/MCTD/	24/14/14/11/5

SLE/overlap syndrome	1/5

Surgical lung biopsy, yes/no	33/41

Corticosteroids/immunosuppressant	23/10

FVC, % predicted	81.0 ± 19.1	38.3–127.0

DLco, % predicted	57.1 ± 19.2	22.6–113.6

RV, % predicted	81.2 ± 31.5	17.9–181.9

TLC, % predicted	80.3 ± 18.3	47.9–138.6

PaO2, mmHg	80.8 ± 9.9	60.2–103.2

A-a gradient, mmHg	20.2 ± 11.5	−3.8–38.1

MPAP, mmHg	17.2 ± 5.5	8–36

CI, l/min/m2	3.59 ± 0.77	1.89–5.18

PVR, Wood units	127.3 ± 59.9	34.0–406.0

PVRI, Wood units/m2	223.5 ± 102.1	52.0–606.0


Characteristic	Non-pregnant women (n = 12)	Pregnant women (n = 12)	P


Gene	LTA from strain	Concentration (μg/mL)	Time

1 h	3 h	24 h

TNF	233	1	4.6 ± 0.3	68 ± 1.8	3.2 ± 0.2


Environmental variables	Childhood diarrhea	COR with 95% CI	AOR with 95% CI

Yes	No

Drinking water source

Protected	16	235	1

Unprotected	168	285	8.658(5.040, 14.873)	2.449(1.264, 4.744)a

Volume of water collected

≤ 15 L/C/d	127	246	2.482(1.737, 3.546)	1.535(1.004, 2.346)a

> 15 L/C/d	57	274	1

Water is shared with livestock at the source

Yes	163	211	11.367(6.985, 18.498)	4.403(2.424, 7.999)a

No	21	309	1

The water storage container is covered at the time of the survey

Yes	2	24	1

No	182	496	4.403(1.030, 18.818)	15.681(0.191, 1287.490)

How to withdraw water from the storage


	Survival	Body Weight	Ascites Fluid (mL) on the 10th Day	Tumour Cells b	Neutrophil c

Day 1	Day 11

)		± 0.5	5	0.6		+

EAC-(BDP+HS)	10/10	23.0 ± 0.5	26.2 ± 0.7	2.6 ± 0.4	-	+

Control	10/10	24.5 ± 0.4	25.1 ± 0.3	0	-	+


Locus	Alleles	Parasitaemia	χ2 significance

Low (< 1,000/μl)	Moderate to high (≥1,000/μl)

Pfcrt 76	Mutant	8	31	<0.001

Wild	23	13

Pfcrt 271	Mutant	0	4	0.138*

Wild	31	40

Pfcrt 326	Mutant	0	9	0.009*

Wild	31	35

Pfcrt 356	Mutant	1	17	<0.001*

Wild	30	27

Pfcrt 371	Mutant	22	36	0.409

Wild	9	8

Pfmdr1 -86	Mutant	0	4	0.138*

Wild	31	40

Pfmdr1 -1246	Mutant	0	3	0.263*

 	Wild	31	41


Data subset	Accuracy	Accuracy (%)	False positives	False negatives	MCC score

All samples	2290 of 2315	98.92	2 of 2159	23 of 156	0.91

EC origin cells	558 of 564	98.94	0 of 535	6 of 29	0.89

EN origin cells	849 of 857	99.07	1 of 790	7 of 67	0.93

M origin cells	1015 of 1030	98.54	3 of 944	12 of 86	0.9

Random non-channel subset	2221 of 2315	95.94	13 of 2006	81 of 309	0.81

Data subset	Accuracy	Accuracy (%)	False positives	False negatives

All samples	2290 of 2315	98.92	2 of 2159	23 of 156

EC origin cells	558 of 564	98.94	0 of 535	6 of 29

EN origin cells	849 of 857	99.07	1 of 790	7 of 67

M origin cells	1015 of 1030	98.54	3 of 944	12 of 86

Random non-channel subset	2221 of 2315	95.94	13 of 2006	81 of 309


Primary antibody	Host	Manufacturer; catalog no.; dilution	Secondary antibody

Enhanced chemiluminescent (ECL) detection

 Anti-phospho-S6 (P-S6) Ser235/236	Rabbit	Cell Signaling Technology, Beverly, MA; #4858; 1:500 in 5 % BSA in TBS-Ta	Anti-rabbit IgG, HRP-conjugated; Cell Signaling Technology, Beverly, MA; #7074; 1:10000 in 5 % nonfat milk in TBS-T

 Anti-S6 (S6)	Rabbit	Cell Signaling Technology, Beverly, MA; #2217; 1:1000 in 5 % BSA in TBS-T

 Anti-mTOR	Rabbit	Cell Signaling Technology, Beverly, MA; #2983; 1:1000 in 5 % BSA in TBS-T

 Anti-caspase-3	Rabbit	Cell Signaling Technology, Beverly, MA; #9662; 1:1000 in 5 % BSA in TBS-T

 Anti-GFP	Rabbit	MBL International Corporation, Geel, Belgium; #598; 1:2000 in 5 % nonfat dry milk in TBS-T

 Anti-Elmo1	Rabbit	Eurogentec, Liege, Belgium; custom orderb; 1:500 in 5 % nonfat dry milk in TBS-T

 Anti-α-tubulin	Mouse	Sigma-Aldrich, St. Louis, MO; #T5168; 1:20,000 in 5 % nonfat dry milk in TBS-T	Anti-mouse IgG, HRP-conjugated; Cell Signaling Technology, Beverly, MA; #7076; 1:10000 in 5 % nonfat milk in TBS-T

 Anti-β-actin-HRP	Mouse	Sigma-Aldrich, St. Louis, MO; A3854; 1:15,000 in 5 % nonfat dry milk in TBS-T	N/A

Immunofluorescence

 Anti-phospho-S6 (P-S6) Ser235/236	Rabbit	Cell Signaling Technology, Beverly, MA; #4858; 1:200 in 1 % donkey serum in PBS-Tc	Anti-rabbit IgG Alexa Fluor 488; Life Technologies, Carlsbad, CA; A-21206; 1:500 in 1 % donkey serum in PBS-T

 Anti-c-Fos	Rabbit	Santa Cruz Biotechnology, Santa Cruz, CA; #7202; 1:200 in 1 % donkey serum in PBS-T

 Anti-GFAP	Mouse	Millipore, Darmstadt, Germany; #04-1031; 1:500 in 1 % donkey serum in PBS-T

 Anti-GFP	Mouse	MBL International Corporation, Geel, Belgium; #598; 1:1000 in GDB bufferd


Type of study	Complete articles	Abstracts	Total	No. of Patients

All studies	8	2	10	249

Prospective	5	1	6	106

Retrospective	3	1	4	143

De novo use of RTX	6	1	7	179

RTX used for refractory AMR	2	1	3	70

Pediatric	1	0	1	20

Adult	7	2	9	229

Type of study	Complete articles	Abstracts	Total	No. of Patients

De novo use of RTX	6	1	7	179

RTX used for refractory AMR	2	1	3	70

Pediatric	1	0	1	20

Adult	7	2	9	229


Strain	Maximum specific growth rate (h-1)

HZ848	0.15 ± 0.01

HZ848-siz1Δ	0.19 ± 0.00

W303a	0.19 ± 0.01

W303a-siz1Δ	0.30 ± 0.01

Strain	Maximum specific growth rate (h-1)

HZ848-siz1Δ	0.19 ± 0.00

W303a	0.19 ± 0.01

W303a-siz1Δ	0.30 ± 0.01


	Initial polysomnography	Titration studya	At therapeutic pressureb

Time in Bed (min)	355	360	84.5

Total Sleep Time (min)	277.5	253	83

Stage N1 (%/min)	3.6/10	4/10	35/29

Stage N2 (%/minutes)	29.2/81	25.1/64	15/12

Stage N3 (%/minutes)	49.5/137	43.3/110	~1/<1

REM (%/minutes)	17.7/49	27.7/70	50/42

Obstructive Apneas	23	1	0

Hypopneas	96	30	4

Central apneas	39	14	1c

REM central apneas	39	14	1c

Mixed apneas	7	0	0

Time below 90% O2 saturation (%)	22.9	4.7	0


	Function	cis element	Sequence	Position	TF family

1	Defense against insect herbivory	AtMYC2 BS in RD22	CACATG	(1578-1583)	BHLH

2	Development	Bellringer/Replumless /Pennywise	AAATTAAA	(2593-2600)	Homeobox

3	Development	Bellringer/Replumless /Pennywise	AAATTAGT	(1368-1375)	Homeobox

4	Development	Bellringer/Replumless /Pennywise	ACTAATTT	(293-300)	Homeobox

5	Response to hiperosmolarity	ATB2/AtbZIP53/AtbZlP44/GBF5 BS in ProDH	ACTCAT	(2537-2542)	bZIP

6	Auxins response	ARFI binding site motif	TGTCTC	(177-182) (1820-1825)	ARF

7	ABA response	DPBF1&2 binding site motif	ACACTAG	(897-904)	bZIP

8		MYB binding site promoter	AACCAAAC	(2359–2366)	MYB

9	Defense and stress	MYB4 binding site motif	AACAAAC	(825-831) (775-781) (2446-2452)	MYB4

10	Leaf maturation and senescence	RAVI-A binding site motif	CAACA	(1-5) (2138-2142) (1508-1512) (583-587) (360-367)	ABI3VPl

11	Development	LFY consensus binding site motif	CCAATG	(1413-1418)	LFY

12		Boxll promoter motif	GGTTAA	(2810-2815)

13	Drought response	DRE-like promoter motif	TACCGACCA	(533-541)

14	Light response	GATA promoter motif [LRE]	TGATAG	(2957-2962)

15	Light response	GATA promoter motif [LRE]	AGATAA	(287-292) (96-101)

16	Light response	GATA promoter motif [LRE]	TGATAA	(2308-2313)

17		Hexamer promoter motif	CCGTCG	(649-654)

18		T-box promoter motif	ACTTIG	(1529-1534)

	Function	cis element	Sequence	Position

15	Light response	GATA promoter motif [LRE]	AGATAA	(287-292) (96-101)

16	Light response	GATA promoter motif [LRE]	TGATAA	(2308-2313)

17		Hexamer promoter motif	CCGTCG	(649-654)

18		T-box promoter motif	ACTTIG	(1529-1534)


Region	States in region	Selected states, medical colleges, and cities

North	Delhi, Rajasthan, Jammu and Kashmir, Himachal Pradesh, Punjab, Haryana, Uttarakhand and Chandigarh	NCT of Delhi (Lady Harding Medical College, Delhi), Rajasthan (NIMS Medical College and Hospital, Jaipur)

South	Tamil Nadu, Karnataka, Kerala, Andhra Pradesh, Puducherry, Lakshadweep, Andaman and Nicobar	Karnataka (Kasturba Medical College, Manipal), Tamil Nadu (Madras Medical College, Chennai)

East	Sikkim, Assam, Tripura, Manipur, Nagaland, Arunachal Pradesh, Mizoram, Meghalaya, Bihar, Jharkhand, West-Bengal and Orissa	Manipur (Regional Institute Medical Sciences, Imphal), Orissa (Kalinga Institute of Medical Sciences, Odisha)

West	Dadar and Nagar Haveli, Daman and Diu, Goa, Maharashtra and Gujarat	Gujarat (M.P. Shah Medical College, Jamnagar), Maharashtra (L.T.M. Medical College and General Hospital, Mumbai)

Central	Uttar Pradesh, Chhattisgarh, and Madhya Pradesh	Uttar Pradesh (Integral Institute of Medical Sciences and Research, Lucknow), Madhya Pradesh (G.R. Medical College, Gwalior)

Region	States in region	Selected states, medical colleges, and cities

North	Delhi, Rajasthan, Jammu and Kashmir, Himachal Pradesh, Punjab, Haryana, Uttarakhand and Chandigarh	NCT of Delhi (Lady Harding Medical College, Delhi), Rajasthan (NIMS Medical College and Hospital, Jaipur)

South	Tamil Nadu, Karnataka, Kerala, Andhra Pradesh, Puducherry, Lakshadweep, Andaman and Nicobar	Karnataka (Kasturba Medical College, Manipal), Tamil Nadu (Madras Medical College, Chennai)

East	Sikkim, Assam, Tripura, Manipur, Nagaland, Arunachal Pradesh, Mizoram, Meghalaya, Bihar, Jharkhand, West-Bengal and Orissa	Manipur (Regional Institute Medical Sciences, Imphal), Orissa (Kalinga Institute of Medical Sciences, Odisha)

West	Dadar and Nagar Haveli, Daman and Diu, Goa, Maharashtra and Gujarat	Gujarat (M.P. Shah Medical College, Jamnagar), Maharashtra (L.T.M. Medical College and General Hospital, Mumbai)

Cent		Uttar Pradesh (Integral Institute of Medic

Region	States in region	Selected states, medical colleges, and cities

ral	Uttar Pradesh, Chhattisgarh, and Madhya Pradesh	al Sciences and Research, Lucknow), Madhya Pradesh (G.R. Medical College, Gwalior)


Risk Factor Goals

Blood Pressure	BP 130/80 mmHg

Diabetes Mellitus	Fasting or pre-prandial glucose of 4-6, or a HbA1C < 6.5%

Lipids	Total cholesterol less than 4 mmol/l or an LDL < 2.0 mmol/l

Smoking	Smoking cessation

Weight	BMI < 25


Strain	SC 5314	opt1Δ	opt2Δ opt3Δ	opt4Δ	opt5Δ	opt1–opt5Δ	ptr2Δ ptr22Δ	opt1–opt5Δ ptr2Δ ptr22Δ

Peptide	MIC (μg mL-1)


Compositional Category	Features in Chloroplast

CP genome length (nt)	155,989

LSC length (nt)	85,912

SSC length (nt)	17,517

IR length (Ira/b) (nt)	52,560

AT/GC contents (%)	62.34/37.66

No. of total/unique genes	129/111

Genic occupancy (nt)	88,065

Intergenic occupancy (nt)	67,924

Protein-coding genes	78

Transfer RNAs (tRNAs)	29

Ribosomal RNAs (rRNAs)	4

No. of genes duplicated in IR regions	16

Total number of genes with intron(s)	17

Gene(s) with single intron	14

Gene(s) with multiple introns	3

tRNAs with intron(s)	5

Compositional Category

CP genome length (nt)

LSC length (nt)

SSC length (nt)

IR length (Ira/b) (nt)

AT/GC contents (%)

No. of total/unique genes

Genic occupancy (nt)

Intergenic occupancy (nt)

Protein-coding genes

Transfer RNAs (tRNAs)

Ribosomal RNAs (rRNAs)

No. of genes duplicated in IR regions

Total number of genes with intron(s)

Gene(s) with single intron

Gene(s) with multiple introns

tRNAs with intron(s)


Data Set	Score Used	Positive	Negative	Close to Zero	Total Tested

Ma–Mu	Sum of signs of translation shift scores	597	569	58	16,942

Fa–Fu	Sum of signs of translation shift scores	48	60	5	15,045

Fa–Fu	Count of CpG	84	85	15	12,491

Data Set	Score Used

Ma–Mu	Sum of signs of translation shift scores

Fa–Fu	Sum of signs of translation shift scores

Fa–Fu	Count of CpG

Positive	Negative	Close to Zero	Total Tested

597	569	58	16,942

48	60	5	15,045

84	85	15	12,491


Participant	Outcome measure	Instrument	baseline	3 months	6 months

Patient	Self-perceived performance in daily activitiesa	Canadian Occupational Performance Measure (COPM; performance rating) [25]	√	√	√

 	Self-perceived satisfaction with performance in daily activities	Canadian Occupational Performance Measure (COPM; satisfaction rating) [25]	√	√	√

 	Objective performance in daily activities	Perceive Recall Plan Perform system (PRPP) [26]	√	√	-

 	Participation	Activity Card Sort (ACS) [27,28]	√	√	-

 	 	Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P; satisfaction part) [29,30]	√	√	√

 	Health-related quality of life	Parkinson’s Disease Questionnaire (PDQ-39) [31-33]	√	√	√

 	Impact of fatigue	Fatigue Severity Scale (FSS) [34,35]	√	√	√

 	Mood	Becks Depression Inventory (BDI) [36]	√	√	√

Caregiver	Perceived caregiver burden	Zarit Burden Interview (ZBI) [37]	√	√	√

 	Objective caregiver burden	Objective care burden questionnaire; hours of care	√	√	√

 	Mood	Hospital Anxiety and Depression Scale (HADS) [38]	√	√	√

Both	Quality of life	Euroqol EQ-5 D [39]	√	-	√

 	Quality of life overall	Visual Analogue Scale for Quality of life; VAS QoL	√	√	√

 	Proactive coping	Utrecht Proactive Coping Competence scale (UPCC) [40]	√	√	√

 	Resource utilization	Resource utilization questionnaire: patient and caregiver version	√	√	√


Birth defects	Number of cases	Birth prevalence/10,000 and 95%CI

Anencephaly	0	0 (0–6.3)

Spin bifida	1	1.7 (0–9.5)

Encephalocele	0	0 (0–6.3)

Microcephaly	1	1.7 (0–9.5)

Arhinencephaly/holoprosencephaly	4	6.8 (1.9–17.4)

Hydrocephaly	4	6.8 (1.9–17.4)

Buphtalmos	1	1.7 (0–9.5)

Congenital cataract	2	3.4 (0.4–12.3)

Anotia/microtia	1	1.7 (0–9.5)

Transposition of great vessels	4	6.8 (1.9–17.4)

Tetralogy of Fallot	2	3.4 (0.4–12.3)

Ventricular septal defect	42	71.3 (51.4–96.4)

Atrial septal defect	4	6.8 (1.9–17.4)

Endocardial cushion defects	3	5.1 (1.1–14.9)

Ebstein's anomaly	1	1.7 (0–9.5)

Hypoplastic left heart syndrome	0	0 (0–6.3)

Coarctation of aorta	3	5.1 (1.1–14.9)

Choanal atresia, bilateral	0	0 (0–6.3)

Cleft palate without cleft lip	1	1.7 (0–9.5)

Cleft lip with or without cleft palate	2	3.4 (0.4–12.3)

Oesophageal atresia/stenosis	4	6.8 (1.9–17.4)

Congenital hypertrophic pyloric stenosis	1	1.7 (0–9.5)

Small intestine atresia/stenosis	0	0 (0–6.3)

Anorectal atresia/stenosis	1	1.7 (0–9.5)

Hirschsprung's disease	1	1.7 (0–9.5)

Anomalies of intestinal fixation	0	0 (0–6.3)

Hypospadias

Indeterminate sex	0	0 (0–6.3)

Renal agenesis	1	1.7 (0–9.5)

Cystic kidney	3	5.1 (1.1–14.9)

Bladder exstrophy	0	0 (0–6.3)

Polydactyly and syndactyly	4	6.8 (1.9–17.4)

Total limb reduction defects	Not analysed	Not analysed

Diaphragmatic hernia	1	1.7 (0–9.5)

Omphalocele	0	0 (0–6.3)

Gastroschisis	0	0 (0–6.3)

Trisomy 13	0	0 (0–6.3)

Trisomy 18	0	0 (0–6.3)

Down syndrome	6	10.2 (3.7–22.2)

Prader Willi syndrome	0	0 (0–6.3)

Total	98	166.4

Birth defects

Anencephaly

Spin bifida

Encephalocele

Microcephaly

Arhinencephaly/holoprosencephaly

Hydrocephaly

Buphtalmos

Congenital cataract

Anotia/microtia

Transposition of great vessels

Tetralogy of Fallot

Ventricular septal defect

Atrial septal defect

Endocardial cushion defects

Ebstein's anomaly

Hypoplastic left heart syndrome

Coarctation of aorta

Choanal atresia, bilateral

Cleft palate without cleft lip

Cleft lip with or without cleft palate

Oesophageal atresia/stenosis

Congenital hypertrophic pyloric stenosis

Small intestine atresia/stenosis

Anorectal atresia/stenosis

Hirschsprung's disease

Anomalies of intestinal fixation

Hypospadias

Indeterminate sex

Renal agenesis

Cystic kidney

Bladder exstrophy

Polydactyly and syndactyly

Total limb reduction defects

Diaphragmatic hernia

Omphalocele

Gastroschisis

Trisomy 13

Trisomy 18

Down syndrome

Prader Willi syndrome

Total


	T2DM	T2DM + MC	Control

CHD, n	37★	55★●	16

1	64	45	None

2	33	47	None

3	13	28●	None


Service area	Number of MNH providers observed	Number of provider-client interactions observed	Intraclass Correlation Coefficient (ICC)

Total	Inter-vention group	Com-parison group	Total	Inter-vention group	Com-parison group	Cluster level	Inter-vention group	Com-parison group

ANC	63	29	34	232	118	114	Facility	0.551	0.458

							Provider	0.763	0.667

Labor & delivery	117	57	60	226	123	123	Facility	0.632	0.474

							Provider	0.775	0.454

PNC	109	57	52	229	119	110	Facility	0.530	0.573

							Provider	0.658	0.574


	Females

Gene	Coefficient estimate	Standard error

AQP9	0.411	0.133

AS3MT	−0.115	0.074

GSTM1	0.107	0.435

SLC39A2	−0.105	0.101


Anti-VLY scFv	Expression level, % of total cell protein	Oligomeric state	Activity (%) after 12 months storage at 4°C

scFv 9B4 (VL-VH)	20-30	monomeric	100

scFv 9B4 (VH-VL)	20-30	monomeric	100

scFv 23A2 (VL-VH)	20-30	monomeric	75

scFv 23A2 (VH-VL)	20-30	monomeric	75


	Plasma membrane number / %	Intracellular number / %	Total immunogold number / %

Dendritic spines	697/32,3	213/9,9	910/42,1

Dendritic shafts	602/27,9	422/19,6	1024/47,4

Axon terminals	172/8	55/2,5	227/10,5

P60

Dendritic spines	798/33,4	241/10,1	1039/43,4

Dendritic shafts	639/26,7	415/17,3	1054/44,1

Axon terminals	232/9,7	67/2,8	299/12,5


Characteristics	% (SE)

Age, yb	45.2 ± 0.2

 < 65	86.2 (0.6)

 ≥ 65	13.8 (0.6)

Sex

 Male	49.5 (0.5)

 Female	50.5 (0.5)

BMI, kg/m2

 < 25	68.9 (0.9)

 ≥ 25	31.1 (0.9)

Smoking exposure

 Never	74.3 (0.7)

 Former or current	25.7 (0.7)

Alcohol drinking, g/day

 < 30	90.1 (0.6)

 ≥ 30	9.9 (0.6)

Residence area

 Rural	20.2 (1.8)

 Urban	79.8 (1.8)

Education

 ≤ High school	70.4 (1.0)

 ≥ College	29.6 (1.0)

Occupation

 Agriculture & fishery	5.6 (0.6)

 Industry	9.2 (0.5)

 Services	85.3 (0.8)

GFR, ml/min/1.73 m2b	95.1 ± 0.5

Blood pressureb

 SBP, mmHg	116.9 ± 0.4

 DBP, mmHg	76.7 ± 0.3

 MAP, mmHg	88.7 ± 0.2


Comparison	Keyword	Gene Set	Gene Set Description	Size	p-valueExp. 2	Significant Genes	p-valueExp. 1

Control vs ALC-NTO/ALC-NTC (see legends)	Growth,Growth Regulation*	GO:0016049GO:0040007	^Cell growth^Growth	4775	0.0020.005	(Ctgf, Igfbp2, Emp1, Osm, Cyr61, Gap43, Crim1, Tgfb3, Igfbp7, Nov, Emp3), Gpc3, Csf1, Socs2, Bmp6, Bmp4, Inhbb, Lepre1, Wrn, Wig1, Cish	0.0100.010

		GO:0001558GO:0040008	Regulation of cell growthRegulation of growth	3956	0.0020.016	(Ctgf, Igfbp2, Osm, Cyr61, Gap43, Crim1, Igfbp7, Nov), Gpc3, Csf1, Socs2,	0.0060.017

		GO:0005520	Insulin-like growth factor binding	14	0.000	Ctgf, Igfbp2, Cyr61, Crim1, Igfbp7, Nov	0.012

	Heart*	GO:0001525	Angiogenesis	53	0.022	Ctgf, Anxa2, Cyr61, Thbs1, Vegfa, Tie1, Elk3, Flt1, Crhr2, Vegfc, Kdr, Bmp4, Adra2b, Tnfrsf12a	0.022

	Eye#	GO:0001654	Eye Development	26	0.040	Mab21l1, Neurod1, Neurod4, Ntrk2, Fkbp8, Bmpr1b, Crb1, Stat3, Tspan5, Pax6, Bmp4, Map3k1	0.004

	Epigenetic factor~,^	GO:0006334	Nucleosome modeling	30	0.021	Hist3h2b, a; Hist1h3f; Hist1h1c; Hist1h2b, c; Hist1h3a; H1f0; Smarca2; Nap1l3	0.033

ALC-NTO vs ALC-NTC	Growth, Growth retardation	GO:0007173	Epidermal growth factor receptor (EGFR) signaling pathway	5	0.019	Pde6g, Egfr, Hbegf(Enriched in ALC-NTC)	0.023


Criterion	Response	No.	Mean ± SD	p-Value

Occupational exposure (mean ± SD)

 Yes	Bone Pb	108	14.4 ± 0.50a	< 0.001

 No		99	3.22 ± 0.50a

 Yes	Blood Pb	107	2.73 ± 2.39	< 0.001

 No		98	1.25 ± 2.10

Smoked ever/never

 Yes	Bone Pb: exposed	65	18.1 ± 0.61a	0.002

 No		43	6.87 ± 0.86a

 Yes	Blood Pb: exposed	64	3.67 ± 12.0	< 0.001

 No		43	1.76 ± 2.49

Ever used estrogen

 Yes	Bone Pb: referent	29	7.73 ± 0.94a	0.003

 No		70	1.41 ± 0.60a

 Yes	Blood Pb: referent	28	1.56 ± 2.21	0.038

 No		70	1.15 ± 2.03

Still have menstrual periods

 Yes	Blood Pb: referent	59	1.04 ± 1.97	0.002

 No		39	1.65 ± 2.14

 Yes	Blood Pb: exposed	46	2.09 ± 2.49	0.012

 No		61	3.33 ± 2.19

Surgical menopause

 Yes	Blood Pb: exposed	47	2.87 ± 2.12	0.008

 No		14	5.46 ± 2.02

Postmenopausal women who have used estrogen

 Yes	Bone Pb: referent	24	9.18 ± 1.08a	0.007

 No		16	1.83 ± 1.32a

Ever used oral contraceptives

 Yes	Bone Pb: referent	73	1.39 ± 0.61a	0.036

 No		26	7.22 ± 0.90a

 Yes	Blood Pb: referent	72	1.13 ± 2.00	0.006

 No		26	1.66 ± 2.66

Criterion	Response

Occupational exposure (mean ± SD)

Yes	Bone Pb

No

Yes	Blood Pb

No

Smoked ever/never

Yes	Bone Pb: exposed

No

Yes	Blood Pb: exposed

No

Ever used estrogen

Yes	Bone Pb: referent

No

Yes	Blood Pb: referent

No

Still have menstrual periods

Yes	Blood Pb: referent

No

Yes	Blood Pb: exposed

No

Surgical menopause

Yes	Blood Pb: exposed

No

Postmenopausal women who have used estrogen

Yes	Bone Pb: referent

No

Ever used oral contraceptives

Yes	Bone Pb: referent

No

Yes	Blood Pb: referent

No


Parameter	(n = 504)

Age (Years)

 <50 Years	422 (84)

 >50 Years	82(16)

Sex

 Male	423(84)

 Female	82(16)

Pre existing comorbid conditions

 Respiratory disease	51 (10)

 Renal Disease	27 (50)

 Malignancy	25 (5)

 Hypertension	11 92)

 Diabetes mellitus	5 (1)

Signs and symptoms

 Pain	495 (98)

 Vomiting	296 (59)

 Abdominal distention	221 (44)

 Constipation	193 (38)

 Fever	124 (25)

 Diarrhoea	35 (7)

 Tachycardia (pulse >/110/minute)	115 (23)

 Hypotention (Systolic blood pressure <100 mm Hg)	44 (9)

 Urine output (<30 ml/hr)	80 (16)

 Tacchypnea (respiratory rate >20/minute)	334 (66)

Investigations

 Pneumoperitoneum on Chest X-Ray	340(67)

 Air fluid levels on abdominal X-Ray	108(21)

 Hyponatraemia(Na<130 mEq/L)	148(29)

 Hypokalemia(K<2.7 mEq/L)	44(09)

 Blood Urea Nitrogen(>167 mg/dl)	76(15)

 Serum Creatinine(<1.7 mg/dl)	65(13)

Parameter	(n = 504)

Age (Years)

<50 Years	422 (84)

>50 Years	82(16)

Sex

Male	423(84)

Female	82(16)

Pre existing comorbid conditions

R	51 (10)

Parameter	(n = 504)

espiratory disease

Renal Disease	27 (50)

Malignancy	25 (5)

Hypertension	11 92)

Diabetes mellitus	5 (1)

Signs and symptoms

Pain	495 (98)

Vomiting	296 (59)

Abdominal distention	221 (44)

Constipation	193 (38)

Fever	124 (25)

Diarrhoea	35 (7)

Tachycardia (pulse >/110/minute)	115 (23)

Hypotention (Systolic blood pressure <100 mm Hg)	44 (9)

Urine output (<30 ml/hr)	80 (16)

Tacchypnea (respiratory rate >20/minute)	334 (66)

Investigations

Pneumoperitoneum on Chest X-Ray	340(67)

Air fluid levels on abdominal X-Ray	108(21)

Hyponatraemia(Na<130 mEq/L)	148(29)

Hypokalemia(K<2.7 mEq/L)	44(09)

Blood Urea Nitrogen(>167 mg/dl)	76(15)

Serum Creatinine(<1.7 mg/dl)	65(13)


Group	n	Before therapy	After therapy

Met + Acu Group	49	5.57 ± 0.257	3.23 ± 0.170***△△

Control Group	49	5.50 ± 0.244	4.25 ± 0.197***


Practice related variables	Percentage (%)

Monitor blood glucose

 Daily	10 (8)

 Weekly	18 (15)

 Monthly	45 (37)

 Never	49 (40)

Blood pressure monitor

 Daily	12 (10)

 Weekly	4 (3)

 Monthly	49 (40)

 Never	57 (47)

Adherence to medication

 Regular	53 (43)

 Irregular	69 (57)

Visiting an eye specialist

 Every 6–12 months	13 (11)

 Every year	45 (37)

 Felt problem with vision	64 (52)


Species	Population	Hostplant	Coordinates

T. bartmani	JL	Abies concolor	34.170000	-117.002017

T. bartmani	RS	Abies concolor	34.210000	-117.098333

T. boharti	ML	Adenostoma	32.881200	-116.445917

T. californicum	Fremont	Adenostoma	36.763517	-121.502533

T. californicum	HW1	Quercus	36.286933	-121.841883

T. chumash	HW2	Adenostoma	34.269700	-118.168483

T. chumash	ED	Ceanothus	33.885183	-116.859783

T. cristinae	WTA	Adenostoma	34.515833	-120.073150

T. cristinae	OJ	Ceanothus	34.485300	-119.298117

T. knulli	Trail	Sequoia	35.836200	-121.391483

T. knulli	BC	Ceanothus	36.071017	-121.595567

T. petita	Ma	Ceanothus	36.358900	-121.900350

T. petita	Mo	Ceanothus	36.476533	-121.936133

T. podura	HW243	Adenostoma	33.815117	-116.791033

T. podura	Seq	Ceanothus	35.583333	-118.533333

T. poppensis	Fish	Pseudotsuga	38.885283	-123.517150

T. poppensis	Mado	Sequoia	36.996433	-121.717783

T. cristinae	OGA	Adenostoma	33.990567	-116.061417

T. cristinae	R23A	Adenostoma	34.519067	-120.077500

T. cristinae	SC	Ceanothus	34.522300	-119.831283

T. cristinae	PEC	Ceanothus	34.491333	-119.795017

Species	Population	Hostplant	Coordinates

T. bartmani	JL	Abies concolor	34.170000	-117.002017

T. bartmani	RS	Abies concolor	34.210000	-117.098333

T. boharti	ML	Adenostoma	32.881200	-116.445917

T. californicum	Fremont	Adenostoma	36.763517	-121.502533

T. californicum	HW1	Quercus	36.286933	-121.841883

T. chumash	HW2	Adenostoma	34.269700	-118.168483

T. chumash	ED	Ceanothus	33.885183	-116.859783

T. cristinae	WTA	Adenostoma	34.515833	-120.073150

T. cristinae	OJ	Ceanothus	34.485300	-119.298117

T. knulli	Trail	Sequoia	35.836200	-121.391483

T. knulli	BC	Ceanothus	36.071017	-121.595567

T. pe	M	Cean	36.3	-12


h-IgA Addition (ng/mL)	Detection (ng/mL)	Recovery

5	.65	95.28%

50	274.93	112.2%


PHASE	ACTIVITY	PURPOSE	LOGISTICS	PARTICIPANTS	OUTPUTS

1.Max.5 × 8hourshifts	Initial unstructuredobservations	• Familiarisation with space and use of space• Familiarisation with rhythm of setting• Starting to build relationships and trust• Determine who is amenable to shadowing• Identify key locations for stationaryobservations• Identify key policy/guideline documents	• Background observation ofactivity (potentiallyaccompanying key initialcontact in the setting)• Introductions with staffmembers• 5 shifts on different days ofthe week (over 2 weeks)(= max 40 hours)	All staff	• Map of settings• Timetable of key regular events• List of 6-8 key informants• Collected documents for lateranalysis (e.g. policies, guidelines)• Fieldnotes

2.Max.8 × 8hourshifts	Shadowing staffmembers	• Observe mechanics of interactionalconstruction of safe practice• Observe interactions newcomers/old-timers• Observe use of tools/artefacts/environment• Identifying key practices to follow in laterstage	• Shadow each staff memberfor 1 shift/part shift• Audio recording of keymeetings attended by staffmember• Field notes of informal talk• Field interviews	2 doctors2 nurses2 allied health2 managers	• Map of practices of each keyinformant - how they construepatient safety and how they goabout trying to maintain it• Fieldnotes• Transcriptions of meetings

3.Max.2 × 8hourshifts	Stationaryobservations in keylocations	• Observe role of key artefacts in constitution ofsafety (e.g. phone in nurse's station; filingcabinet etc).• Observe patterns of movement of staff	• 2 locations, 1 shift each(max. 16 hours)	All staff	• Fieldnote account of how artefactsand space play a role in theconstitution of safety• Actor-artefact network map

4.Max.4 × 8hourshifts	Tracing keypractices	• Observe the unfolding of specific practicespreviously identified as key to preservation ofsafety• Observe differences in activity when practice isin the course of the everyday (e.g. admission/discharge) and, if appropriate, when it followsbreakdown in order (e.g. incident review)	• 1 'everyday' practice overthe course of 2 shifts• 1 practice dealing withdeviation from the normal (i.e.when safe practice hasbroken down in some way)	Staff involved inpractices chosen	• Map of 'practice nets' involved inpractices key to preservation ofsafety• How practice nets change whensafety breaks down

5.Approx.1 hr perinterview	Interviews	• Elicit narrative accounts of safety preservation• Observe how the meaning of safety isconstructed by different professionals - what'rules and resources' do they draw on?• Test emerging findings/maps of practices	• 6-8 interviews - audiorecordings	6-8 key informantsfrom phase 2	• Transcripts for analysis

6.Approx.30 minspersurvey	•Social networksurvey	• Provide triangulation of observation andinterview data• Map overall patterns of communication aboutsafety issues within and between the twosettings under study	• Administer a social networkquestionnaire to all staff in theinpatient team andcommunity team under study.	All staff	• Social network diagrams providingvisual representation of patterns ofsafety communication

PHASE	ACTIVITY	PURPOSE	LOGISTICS	PARTICIPANTS	OUTPUTS

1.Max.5 × 8hourshifts	Initial unstructuredobservations	• Familiarisation with space and use of space• Familiarisation with rhythm of setting• Starting to build relationships and trust• Determine who is amenable to shadowing• Identify key locations for stationaryobservations• Identify key policy/guideline documents	• Background observation ofactivity (potentiallyaccompanying key initialcontact in the setting)• Introductions with staffmembers• 5 shifts on different days ofthe week (over 2 weeks)(= max 40 hours)	All staff	• Map of settings• Timetable of key regular events• List of 6-8 key informants• Collected documents for lateranalysis (e.g. policies, guidelines)• Fieldnotes

2.Max.8 × 8hourshifts	Shadowing staffmembers	• Observe mechanics of interactionalconstruction of safe practice• Observe interactions newcomers/old-timers• Observe use of tools/artefacts/environment• Identifying key practices to follow in laterstage	• Shadow each staff memberfor 1 shift/part shift• Audio recording of keymeetings attended by staffmember• Field notes of informal talk• Field interviews	2 doctors2 nurses2 allied health2 managers	• Map of practices of each keyinformant - how they construepatient safety and how they goabout trying to maintain it• Fieldnotes• Transcriptions of meetings

3.Max.2 × 8hourshifts	Stationaryobservations in keylocations	• Observe role of key artefacts in constitution ofsafety (e.g. phone in nurse's station; filingcabinet etc).• Observe patterns of movement of staff	• 2 locations, 1 shift each(max. 16 hours)	All staff	• Fieldnote account of how artefactsand space play a role in theconstitution of safety• Actor-artefact network map

4.Max.4 × 8hourshifts	Tracing keypractices	• Observe the unfolding of specific practicespreviously identified as key to preservation ofsafety• Observe differences in activity when practice isin the course of the everyday (e.g. admission/discharge) and, if appropriate, when it followsbreakdown in order (e.g. incident review)	• 1 'everyday' practice overthe course of 2 shifts• 1 practice dealing withdeviation from the normal (i.e.when safe practice hasbroken down in some way)	Staff involved inpractices chosen	• Map of 'practice nets' involved inpractices key to preservation ofsafety• How practice nets change whensafety breaks down

5.Approx.1 hr perint	Intervi	• Elicit narrative accounts of safety preservation• Observe how the meaning of safety isconstructed by different professionals -	• 6-8 interviews - audiorecordings	6-8 key informantsfr	• Transcripts f

PHASE	ACTIVITY	PURPOSE	LOGISTICS	PARTICIPANTS	OUTPUTS

erview	ews	 what'rules and resources' do they draw on?• Test emerging findings/maps of practices		om phase 2	or analysis

6.Approx.30 minspersurvey	•Social networksurvey	• Provide triangulation of observation andinterview data• Map overall patterns of communication aboutsafety issues within and between the twosettings under study	• Administer a social networkquestionnaire to all staff in theinpatient team andcommunity team under study.	All staff	• Social network diagrams providingvisual representation of patterns ofsafety communication


	Mycotoxin Content (μg/kg) a

	% >LOD	Mean	SEM b	Median	90th Percentile	Maximum

DON	66	473	99	100	2510	9880

ZEA	22	18	7	5	47	1000

NIV	25	16	3	3	75	290


Country	Discount	Annual cash flow (profit/loss)	Present value of annual cash flow	Present value of all annual cash flows	Present value of terminal valuea	Total present valueb

Singapore	50% annually	3.13	0.41	1.51	4.13	5.64

25% annually	3.13	1.03	3.15	10.27	13.41

15% annually	3.13	1.56	4.42	15.58	20.00

Netherlands	50% annually	10.76	1.42	6.06	14.17	20.23

25% annually	10.76	3.53	12.12	35.27	47.39

15% annually	10.76	5.35	16.80	53.51	70.31

USA	50% annually	−94.76	0	0	0	0

25% annually	−94.76	0	0	0	0

15% annually	−94.76	0	0	0	0

Country	Discount	Annual cash flow (profit/loss)	Present value of annual cash flow	Present value of all annual cash flows	Present value of terminal valuea	Total present valueb

USA	50% annually	−94.76	0	0	0	0

25% annually	−94.76	0	0	0	0

15% annually	−94.76	0	0	0	0


Order	 Symbol	Name	Similarity	Parameter	Remark

1	CENP-E	kinesin	0. 8169	3

2	GCN4	 	0.7611	3	monomer yeast transcriptional activator

3	ROCK1	Serine kinase	0.7394	3	Rho-associated,coiled-coil containing protein kinase 1

6	CENP-B	 	0.7297	3

4	PAK1	 	0.6481	3	P21 activated kinase

7	GP41-HIV	 	0. 6010	3

8	ATG12	 	0.4749	3

5	ROCK2	 	0.4478	3

9	CENP-A	 	0	0

Order	Symbol

1	CENP-E

2	GCN4

3	ROCK1

6	CENP-B

4	PAK1

7	GP41-HIV

8	ATG12

5	ROCK2

9	CENP-A

Name	Similarity	Parameter	Remark

kinesin	0. 8169	3

	0.7611	3	monomer yeast transcriptional activator

Serine kinase	0.7394	3	Rho-associated,coiled-coil containing protein kinase 1

	0.7297	3

	0.6481	3	P21 activated kinase

	0. 6010	3

	0.4749	3

	0.4478	3

	0	0


high secure-intensive care	Male admission/high secure	Male medium secure-1	Male medium secure-2	Long term low security	Male low secure rehab	Male pre-discharge/community h1gh support	ANOVADf = 6


Measurementa	No. (%)

Range of motion (knee)	34 (57)

X-ray (knee)	19 (32)

Pain score (knee)	10 (17)

Subjects were asked to first stand and then walk along a 10 m walkway	5 (8)

Range of motion (shoulder)	5 (8)

Pain score (shoulder)	5 (8)

Stability of joint function (stabilometry)	4 (7)

Pain score (upper limb)	4 (7)

Hand grip strength	3 (5)

Range of motion (hip)	3 (5)

Strength of the knee extensors	3 (5)

Chair rise test	2 (3)

Muscle power (shoulder)	2 (3)

Range of motion (ankle)	2 (3)

Range of motion (finger/wrist)	2 (3)

Range of motion (lower limb, matching task)	2 (3)

X-ray (elbow)	2 (3)

X-ray (hip)	2 (3)

X-ray (shoulder)	2 (3)

Measurementa	No. (%)

Chair rise test	2 (3)

Muscle power (shoulder)	2 (3)

Range of motion (ankle)	2 (3)

Range of motion (finger/wrist)	2 (3)

Range of motion (lower limb, matching task)	2 (3)

X-ray (elbow)	2 (3)

X-ray (hip)	2 (3)

X-ray (shoulder)	2 (3)


Compound	Adsorption capacity, μmol g−1	Distribution coefficient (k), g L−1

1-Naphthol	62	200

2-Naphthol	60	170

Resorcinol	59	190

Phenol	0 ± 2	–

Compound	Adsorption capacity, μmol g−1

1-Naphthol	62

2-Naphthol	60

Resorcinol	59

Phenol	0 ± 2

Distribution coefficient (k), g L−1

200

170

190

–


Group 1	Group 2	Chi-square	Significance (p value)


	Seroprotection status

Vaccine strain		Young cohort (n = 58)

		Placebo

		n/N (%)

A/California/7/2009 (H1N1)	Before	20/29 (69)a

After	29/29 (100)

A/Perth/16/2009 (H3N2)	Before	10/29 (34)

After	26/29 (90)

B/Brisbane/60/2008	Before	4/29 (14)

After	28/29 (97)


	Creatinine-Cystatin C-based eGFR, ml/min/1.73 m2	C-reactive protein levels, mg/L

≥60(n = 1750)	<60(n = 605)	P-value	<3(n = 1564)	≥3(n = 791)	P-value

Serum cystatin C, mg/L	0.89 ± 0.13	1.41 ± 0.42	<0.001	0.96 ± 0.24	1.15 ± 0.42	<0.001


4	—	—	17 (10.30)	1.51 (0.44, 5.21)	17 (10.30)	2.22 (0.55, 9.01)	13 (7.88)	2.02 (0.49, 8.39)

5	25 (13.97)	1.70 (0.36, 7.94)	17 (9.29)	2.66 (0.47, 15.06)	19 (10.38)	4.45 (1.31, 15.14)	16 (8.74)	4.80 (1.19, 19.26)

Adjusted for maternal age at enrollment, race, education, marital status, maternal serum cotinine concentrations at enrollment, maternal IQ, child sex, maternal depression, household income, and HOME Inventory score.


Serum samples against:	Clade	HI titer (log2) against	HA identity*

TK16	Homologous antigen

A/chicken/Egypt/AR234-FAOF8NLQP/2014 (H5N1)	2.2.1.2	7	9	99.4/100

A/chicken/Egypt/0879-NLQP/2008 (H5N1)	2.2.1.1	5	10	94.7/94.2

Serum samples against:	Clade	HI titer (log2) against	HA identity*

TK16	Homologous antigen

A/teal/Germany/WV632/2005 (H5N1)	2.2	6	9	88.7/90.6

A/turkey/Germany-MV/R2472/2014 (H5N8)	2.3.4.4	2	7	88.7/90.6

A/Vietnam/1194/2004 (H5N1)	1	6	8	93.2/95.1


Parameters	Pre-treatment	First weekpost-treatment	Second weekpost-treatment

Volume of ejaculate (ml)	0.30 ± 0.02 *	0.23 ± 0.02	0.15 ± 0.02*

Color of ejaculate	Milky to creamy white	Milky to creamy white	Milky to creamy white

Sperm motility 	85% *	80%	70% *

Spermatozoa viability	96% *	90%	83% *

Sperm concentration (x 109/ml)	428 ± 4.26 *	341 ± 6.63 *	289 ± 4.81*


Variable	N° total dogs	N° positiveT. annaedog (%)

Age (years)	≤3	65	53 (81.54)**

>3	47	22 (46.81)

unknown	8	0

Sex	Male	58	38 (65.5)

Female	55	37 (67.2)

unknown	7	0

Size (kg)	≤22	77	59 (76.6)*

>22	35	16 (45.71)

unknown	8	0

Breed	Pure breed	86	53 (61.6)

Crossbreed	33	22 (66.6)

unknown	1	0

Lifestyle	Hunting	75	56 (74.6)*

Companion	28	13 (46.4)

Guard	12	6 (50)

unknown	5	0

Habitat	Rural	96	64 (66.6)

Urban	24	11 (45.8)

Tick infestation	Yes	50	35 (70)

No	49	27 (55.1)

unknown	21	13 (10.8)

Seasonality	spring	20	14 (70)

summer	20	10 (50)

autumn	60	38 (63.3)

winter	20	13 (65)

Lifestyle	unknown	5	0

Habitat	Rural	96	64 (66.6)

Urban	24	11 (45.8)

Tick infestation	Yes	50	35 (70)

No	49	27 (55.1)

unknown	21	13 (10.8)

Seasonality	spring	20	14 (70)

summer	20	10 (50)

autumn	60	38 (63.3)

winter	20	13 (65)


Parameter	Correlation coefficient (r)	p value

CD11avs.sICAM-1	0.317	>0.01

CD11avs.sVCAM-1	0.366	> 0.01

CD11bvs.sICAM-1	0.251	> 0.05

CD11bvs. sVCAM-1	0.258	> 0.05

CD49dvs.sICAM-1	0.315	>0.01

CD49dvs.sVCAM-1	0.419	> 0.01

sICAM-1vs.TNF-α	0.355	>0.01

sVCAM-1vs.TNF-α	0.419	> 0.01

Parameter	Correlation coefficient (r)	p value

CD11avs.sICAM-1	0.317	>0.01

CD11avs.sVCAM-1	0.366	> 0.01

CD11bvs.sICAM-1	0.251	> 0.05

CD11bvs. sVCAM-1	0.258	> 0.05

CD49dvs.s	0.31


Male	60 (67%)

Age

 20–40 years of age	52 (58%)

 41–50 years of age	21 (23%)

 >50 years of age	17 (19%)

Practitioner type

 Attending physician	56 (62%)

 Resident	13 (14%)

 Extender	21 (23%)

Experience

 1–5 years	38 (42%)

 >5–10 years	15 (17%)

 >10 years	37 (41%)

Practice facility

 Academic	54 (60%)

 Private or community	32 (36%)

 Urgent care	4 (4%)

Average annual census

 <30 k	5 (6%)

 30–75 k	33 (37%)

 >75 k	52 (57%)


Parameter	South Asian	Western European	p-value

WB SAS	0.7 ± 0.8	1.8 ± 2.3	0.10

Head/neck SAS	0.5 ± 1.1	1.9 ± 4.0	0.21

Aorta SAS	0.9 ± 2.6	1.3 ± 3.1	0.59

Abdomen SAS	1.8 ± 3.8	3.2 ± 4.4	0.26

Iliofemoral SAS	0.0 ± 0.0	1.9 ± 6.9	0.048

Run-off SAS	0.7 ± 2.2	0.9 ± 2.9	0.77

Normal vessels	501 (97%)	1117 (95%)	0.2

Vessels with 1–50% stenosis	14 (3%)	46 (4%)	0.1

Vessels with 51–70% stenosis	1 (0.2%)	9 (0.8%)	0.08

Vessels with 71–99% stenosis	0	3 (0.2%)	0.3

Occluded vessels	0	1 (0.01%)	0.3

Parameter	South Asian

WB SAS	0.7 ± 0.8

Head/neck SAS	0.5 ± 1.1

Aorta SAS	0.9 ± 2.6

Abdomen SAS	1.8 ± 3.8

Iliofemoral SAS	0.0 ± 0.0

Run-off SAS	0.7 ± 2.2

Normal vessels	501 (97%)

Vessels with 1–50% stenosis	14 (3%)

Vessels with 51–70% stenosis	1 (0.2%)

Vessels with 71–99% stenosis	0

Occluded vessels	0


Occupational exposure	Never smokers	Former smokers	Current smokers	P valueb

No.	%	No.	%	No.	%

Never exposed	52	70.3	38	48.7	32	69.6	Reference

Ever exposed (any agent)	22	29.7	40	51.3	14	30.4	0.01

 Wood dust	12	16.2	21	26.9	10	21.7	0.10

 Leather dust	10	13.5	17	21.8	2	4.3	0.01

 Nickel compounds	0	0.0	2	2.6	2	4.3	0.23

 Chromium compounds	1	1.4	3	3.8	0	0.0	0.16

 PAH	0	0.0	1	1.3	1	2.2	0.47

 Cork dust	1	1.4	0	0.0	0	0.0	0.51

Occupational exposure	Never smokers	Former smokers

No.	%	No.

Never exposed	52	70.3	38

Ever exposed (any agent)	22	29.7	40

Wood dust	12	16.2	21

Leather dust	10	13.5	17

Nickel compounds	0	0.0	2

Chromium compounds	1	1.4	3

PAH	0	0.0	1

Cork dust	1	1.4	0


RIO—Psychosocial Measure	Coefficient of Correlation

Temp. Fingers—Temp. Nose	0.450	**

—Interference General (BPI)	−0.390	*

—Interference Affective (BPI)	−0.517	*

—Interference Relationship (BPI)	−0.437	*

—Interference Sleep (BPI)	−0.600	***

—Interference Enjoy (BPI)	−0.665	***

—Pain (NAS of SF-MPQ)	−0.584	**

—Loneliness (L-UCLA)	−0.487	**

Temp. Chin—Temp. Maxillofacial	0.483	**

—Temp. Nose	0.459	**

—Internal Control of Anger (STAXI-2)	0.383	*

—Alexithymia (TAS)	−0.446	*

—Supression (EQR)	−0.481	*

Temp. Maxillary—Temp. Nose 	0.821	***

—Interference Sleep (BPI)	−0.520	**

—Interference Enjoy (BPI)	−0.461	**

—Pain (NAS of SF-MPQ)	−0.504	**

Temp. Nose—Interference Sleep (BPI)	−0.443	*

—Pain (NAS of SF-MPQ)	−0.413	*

Temp. Periorbital—Temp. Forehead	0.469	**

—Reappraisal (EQR)	−0.485	*


Experiment	Total reads	Aligned reads	Mean PCR duplicates (%)	Aligned reads on target	On-target rate (%)	Uniquely aligned readsa	Uniquely aligned reads on targeta	On-target rate (%)a	Mean coverage on target

dCATCH-SeqCATCH-Seq	853,358841,154	414,965802,931	47.42.8	382,625291,808	92.2136.34	406,331762,445	379,084289,558	93.2937.98	145.98110.18

E	Total rea	Align	Mean PCR d	Aligned re	On-target r	Uniquel	Uniquely aligned reads	On-tar	Mean coverag


Regression indices and explanatory variable	Dependent variable‡

Eggs	Excreta

Intercept	-1.33** (0.45)	2.97** (0.23)

Regression coefficients

Area (Reference: Faridpur)

Madaripur	0.46** (0.15)	0.09 (0.08)

Chandpur	-0.29* (0.15)	0.01 (0.08)

Satkhira	-0.28 (0.15)	0.02 (0.08)

Jessore	-0.22 (0.15)	0.03 (0.08)

Age (weeks)	0.01** (0.00)	-0.00 (0.00)

Feed type (Reference: Commercial feed)	0.00 (0.13)	0.06 (0.07)

Arsenic in drinking-water (ppb)	0.41** (0.03)	0.44** (0.02)

Arsenic in feed (ppb)	0.40** (0.09)	0.52** (0.04)

R2	0.55	0.82

F value	36.83**	133.42**


Species	Accession used for sequencing	Raw paired-end reads (DNA-, RNA-seq) (M)	Trimmed paired-end reads (DNA-, RNA-seq) (M)	Repetitive fraction (%) (SE)


Predictor	β coefficient	95% CI	Unadjusted p valuea

Pre-morbid employment	0.54	−0.16 to 1.24	0.131

Return to same employment	2.08	1.06–3.10	<0.001

Time off from work	0.51	0.20–0.82	0.001


Secure environment (SE) employment type	Less than 10 years	11 – 20 years	21 – 30 years	Over 30 years	TOTAL

GPs predominantly employed in SE	3	8	8	4	23

GP principals	1	2	4	2	9

TOTAL	4	10	12	6	32

Secure environment (SE) employment type	Less than 10 years	11 – 20 years	21 – 30 years	Over 30 years	TOTAL

GPs predominantly employed in SE	3	8	8	4	23

GP pr	1		4		9

Secure environment (SE) employment type	Less than 10 years	11 – 20 years	21 – 30 years	Over 30 years	TOTAL

incipals		2		2

TOTAL	4	10	12	6	32


	National sponsors	International sponsors

When to report adverse events	Frequency	Frequency

Serious adverse events

 No later than 1 hour	0	0

 No later than 24 hours	0	31

 No later than 7 days	1	2

 No later than 15 days	0	1

 Others	0	5

 Did not specify	30	32

 Total	31	71

Unexpected adverse events

 No later than 1 hour	0	1

 No later than 24 hours	0	12

 No later than 7 days	1	1

 No later than 15 days	0	3

 Others	0	6

 Did not specify	30	48

 Total	31	71

	National sponsors	International sponsors

When to report adverse events	Frequency	Frequency

Serious adverse events

No later than 1 hour	0	0

No later than 24 hours	0	31

No later than 7 days	1	2

No later than 15 days	0	1

Others	0	5

Did not specify	30	32

Total	31	71

Unexpected adverse events

No later than 1 hour	0	1

No later than 24 hours	0	12

No later than 7 days	1	1

No la		3

ter than 15 days	0

Others	0	6

Did not specify	30	48

Total	31	71


	Mean (SD) or %

Age, mean (SD)	63.5 (13.8)

 18–45, %	11.5%

 46–70, %	51.5%

≥ 71, %	37.0%

Male, %	35.3%

Marital status, %

 Married	70.7%

 Single	3.7%

 Widowed/Separated/divorced	25.6%

Living alone, %	15.2%

Level of education, %

≤ Elementary	47.9%

 Middle School	16.7%

 High School	23.8%

≥ University	11.7%

Employment status, %

 Regular/long-term	25.0%

 Non-regular/temporary	23.5%

 Unemployed	2.5%

 Economically inactive/students	50.0%

Medical aid, %	8.3%

Perceived social status	3.6 (1.5)


Group	HC (n = 21)	Mild AD (n = 17)	AD-MCI (n = 23)	p

Female	13	7	11	0.42

Male	8	10	12


Clinical features	Pathoanatomy	Treatment based approach	Screening/Prediction tool	Pain mechanisms

Barker 1990 [79]	2	Bernard and Kirkaldy Willis 1987 [41]	2	Albert et al. 2012 [61]	4	Fritz et al. 2007 [64]	3	Schafer et al. 2009 [65]	5

Ben Debba et al. 2000 [36]	3.5	Cassisi et al. 1993 [38]	3	Hall et al. 1994 [49]	5	Roach et al. 1997 [63]	3	Smart et al. 2011 [66]	5

Glassman et al. 2011 [37]	2.5	Hahne et al. 2011 [38]	3	Mckenzie 1981 [49]	5.5	Scholz et al. 2009 [62]	4	Nijs et al. 2015 [75]	2.5

Nachemson and Andersson 1982 [80]	3.5	Paatelma et al. 2009 [44]	3.5	Delitto et al. 2012 [48]	3.5

Spitzer et al. 1987 [25]	4	Petersen et al. 2003 [39]	4

Sweetman et al. 1992 [26]	2.5	Vining et al. 2013 [46]	3.5

Clinical features	Pathoanatomy	Treatment based approach	Screening/Prediction tool	Pain mechanisms

		Bernard 	2		4		3	Schafer e	5

Barker 1990 [79]	2	and Kirkaldy Willis 1987 [41]		Albert et al. 2012 [61]		Fritz et al. 2007 [64]		t al. 2009 [65]

Ben Debba et al. 2000 [36]	3.5	Cassisi et al. 1993 [38]	3	Hall et al. 1994 [49]	5	Roach et al. 1997 [63]	3	Smart et al. 2011 [66]	5

Glassman et al. 2011 [37]	2.5	Hahne et al. 2011 [38]	3	Mckenzie 1981 [49]	5.5	Scholz et al. 2009 [62]	4	Nijs et al. 2015 [75]	2.5

Nachemson and Andersson 1982 [80]	3.5	Paatelma et al. 2009 [44]	3.5	Delitto et al. 2012 [48]	3.5

Spitzer et al. 1987 [25]	4	Petersen et al. 2003 [39]	4

Sweetman et al. 1992 [26]	2.5	Vining et al. 2013 [46]	3.5


Gene	Primer	Sequence	Amplicon	Tm (°C)

GK	Forward	5′-CATATGTGCTCCGCAGGACTA-3′	105 bp	61.7

	Reverse	5′-CTTGTACACGGAGCCATCCA-3′

HK	Forward	5′-ACCCACGAAACAACACCATCA-3′	69 bp	79

	Reverse	5′-GACGTACAACAATGGCTCACTAAAG-3′

PFK-1 (L)	Forward	5′-TTACCGATCACCCTCGTTCCT-3′	80 bp	84

	Reverse	5′-TTCCCCTTAGTGCTGGGATCT-3′

PFK-1 (M)	Forward	5′-GTGGACACTGATATGACCATTGG-3′	67 bp	82

	Reverse	5′-ATGGCGTCCACGATCTCTACA-3′

G6Pase	Forward	5′-GGATCTACCTTGCGGCTCACT-3′	132 bp	62.7

	Reverse	5′-TGTAGATGCCCCGGATGTG-3′

F16BP	Forward	5′-CGTCCTATGCTACCTGTGTCCTT-3′	73 bp	81

	Reverse	5′-CCCCTCTTCTCGGGCTCTATTAT-3′

PEPCK	Forward	5′-GCAACTTCTCTCGGCTCGTT-3′	99 bp	62.7

	Reverse	5′-TGGCAGTTCTACTGGGCTACAC-3′

G6PDH	Forward	5′-GATGGCCTTCTACCCGAAGAC-3′	72 bp	82

	Reverse	5′-GCGGATGTCATCCACTGTGA-3′

P13K	Forward	5′-CCTGAAAGAGCTGGTGCTACATT-3′	71 bp	81

	Reverse	5′-GTGTGACATTGAGGGAGTCATTG-3′

Gene	Primer	Sequence	Amplicon	Tm (°C)

GK	Forward	5′-CATATGTGCTCCGCAGGACTA-3′	105 bp	61.7

	Reverse	5′-CTTGTACACGGAGCCATCCA-3′

HK	Forward	5′-ACCCACGAAACAACACCATCA-3′	69 bp	79

	Reverse	5′-GACGTACAACAATGGCTCACTAAAG-3′

PFK-1 (L)	Forward	5′-TTACCGATCACCCTCGTTCCT-3′	80 bp	84

	Reverse	5′-TTCCCCTTAGTGCTGGGATCT-3′

PFK-1 (M)	Forward	5′-GTGGACACTGATATGACCATTGG-3′	67 bp	82

	Reverse	5′-ATGGCGTCCACGATCTCTACA-3′

G6Pase	Forward	5′-GGATCTACCTTGCGGCTCACT-3′	132 bp	62.7

	Rev	5′-TGTAGATGC

	erse	CCCGGATGTG-3′

F16BP	Forward	5′-CGTCCTATGCTACCTGTGTCCTT-3′	73 bp	81

	Reverse	5′-CCCCTCTTCTCGGGCTCTATTAT-3′

PEPCK	Forward	5′-GCAACTTCTCTCGGCTCGTT-3′	99 bp	62.7

	Reverse	5′-TGGCAGTTCTACTGGGCTACAC-3′

G6PDH	Forward	5′-GATGGCCTTCTACCCGAAGAC-3′	72 bp	82

	Reverse	5′-GCGGATGTCATCCACTGTGA-3′

P13K	Forward	5′-CCTGAAAGAGCTGGTGCTACATT-3′	71 bp	81

	Reverse	5′-GTGTGACATTGAGGGAGTCATTG-3′


Sampling time (expression change)	Ischemia-related	PACAP-related	PACAP in ischemia-related	Common: ischemia-related and PACAP in ischemia-related	Common: PACAP-related and PACAP in ischemia-related

6 h (upregulated)	1,237	435	839	171	43

6 h (downregulated)	622	743	498	31	24

24 h (upregulated)	2,759	263	831	49	30

24 h (downregulated)	2,104	271	1468	28	75


	JIA-associated NIU (n = 14)	Pure NIU (n = 11)	Total

Bilateral (pts)	12/14	11/11	23/25

Total eyes with NIU	24	22	46

Location:

Anterior/Posterior/Panuveitis	12/6/2	2/4/2	16/7/2


Reference	Strains	Plasmids	Time (h)	IPTG-conc. (mM)	RPM (1/min)	Temperature (°C)	δ-ALA-conc. (mM)	Thiamin-conc. (mM)

[46]	BL21(DE3)	pET28a	2	0.2		25

			4	0.5		30

			6	0.8		34

			8	1		37

Reference	Strains	Plasmids	Time (h)	IPTG-conc. (mM)	RPM (1/min)	Temperature (°C)	δ-ALA-conc. (mM)	Thiamin-conc. (mM)

			10

[49]	JM109	pCWori	12	0.2	150	18	0.2	0.5

	DH5α	pET28a	20	0.4	170	25	0.4	1

	C100	pTreHis	24	0.6	200	30	0.6	1.5

	DE3		30	0.8	250	37	0.8

	CodonPlus

	Pril


	Current	Projected

		Only MVA3	MVA/Misoprostol4

Procedure type distribution for first trimester, legal, induced abortion

MVA ($17)		100 %	70 %

Misoprostol-alone ($10)		-	30 %

Total annual cost	$314,008[$287,406 - $502,522]	$250,332	$219,408

Percent decrease from current costs	-	20 %	30 %

	Current

Procedure type distribution for first trimester, legal, induced abortion

MVA ($17)

Misoprostol-alone ($10)

Total annual cost	$314,008[$287,406 - $502,522]

Percent decrease from current costs	-

Projected

Only MVA3	MVA/Misoprostol4

Procedure type distribution for first trimester, legal, induced abortion

100 %	70 %

-	30 %

$250,332	$219,408

20 %	30 %


Clinical parameter	SLE patients	Healthy Controls	P value

Patients (number)	52	52	–

Age (years)	31 (12–52)	32 (20–56)	0.438

Female:Male ratio	46:6	45:7	0.767

Laboratory data

TG (mmol/L)	1.62 (0.50–8.93)	0.80 (0.35–2.52)	<0.001

TC (mmol/L)	4.18 (1.92–9.28)	4.28 (3.25–5.52)	0.207


Compound	Inhibitor concentration (mg/L)

Furfural	19.65 ± 0.81

Hydroxymethylfurfural (HMF)	3.89 ± 0.25

Glucuronic acid	ND

p-coumaric acid	ND

Syringic acid	ND

Ferulic acid	ND

Compound	Inhibitor concentration (mg/L)

Glucuronic acid	ND

p-coumaric acid	ND

Syringic acid	ND

Ferulic acid	ND


Targeted neurotransmitter	Agents under investigation	Status	Ref.

Acetylcholine	LatrepirdineHuperzine A	(III)	76

GABA	SGS742	(II)*

ADS‐8704 (NMDA antagonist)	(III)

Serotonin	5HT1A	Lecozotan	(II)

5‐HT4	PRX‐03140TD‐8954	–

5‐HT6	SB‐742457	(II)

Histamine	PF03654746AB288	(I)(II)

Adenosine	SCH58261	–

Targeted neurotransmitter	Agents under investigation	Status

Adenosine	SCH58261	–


Factors	Outcome (n = 10)

Boiling/treatment of drinking water:	Yes	0

No	10 (100%)

Regular hand washing after toilet use:	Yes	3 (30%)

No	7 (70%)

Regular hand washing after handling pork with:	Soap	9 (90%)

Sanitizer	0

Water only	1 (10%)

Wearing of hand gloves and aprons at work:	Yes	0

No	10 (100%)

Consumption of pork:	Yes	10 (100%)

No	0

Roasting and eating pork while handling raw pork:	Yes	4 (40%)

No	6 (60%)

Method of pork processing for consumption:	Cooked	4 (40%)

Cooked and fried	2 (20%)

Roasted	4 (40%)

Knowledge on public health significance of Taenia solium:	Yes	0

No	10 (100%)


Downy mildew (Sclerospora graminicola)	ICMPE #13-6-30, 134-6-9, 134-6-34, 13-6-27, 37, and 71;ICML #1, 2, 3, 4, 5, 6, 7, 8, 9, 10; ICMA #91333, 91444, and 91555; ICMA 92666 and ICMB 92666 (resistant to ergot, smut, and downy mildew)	Thakur et al., 1982; Willingale et al., 1986; Thakur and King, 1988a,b; Thakur et al., 1992; Rai et al., 1998b; Khairwal and Yadav, 2005

Ergot (Claviceps fusiformis)	ExB 46-1-2-S-2, ExB 112-1-S-1-1, ICMV 8282, ICMV8283; ICMA 88006A and ICMA 88006B (resistant to smut and downy mildew);ICMA#91333, 91444 and 91555; 44 accessions selected from the screening of 1747 germplasm; ICML #5–10; ICMPS #100-5-1, 700-1-5-4, 900-1-4-1, 900-3-1, 900-9-3, 1300-2-1-2, 1400-1-6-2, 1600-2-4, 1500-7-3-2, 1800-3-1-2, and 2000-5-2; SSC FS 252-S-4, ICI 7517-S-1, ExB 132-2-S-5-2-DM-1, and P-489-S-3; SSC 46-2-2-1, SC 77-7-2-3-1, SSC 18-7-3-1	Thakur et al., 1983; Thakur and King, 1988c; Yadav and Duhan, 1996; Rai et al., 1998a; Khairwal and Yadav, 2005

Smut (Moesziomyces penicillariae)	ICML #5, 6, 7, 8, 9, and 10; ICML #17, 18, 19, 20 and 21; Tif leaf 3; Tift 3 (PI 547035) and Tift 4 (PI 547036); Tift 65 (resistant to rust and leaf spot)	Bourland, 1987; Thakur and King, 1988a; Wilson and Burton, 1991; Burton and Wilson, 1995; Hanna et al., 1997

Rust (Puccinia sp.)	IP #16438 and 16762; P 310-17 and P 1449-3; IP18292; IP18293;700651; ICML #12, 13, 14, 15, 16, and 22; ICMP #312, 423, and 85410; 7042S; 841A; IP #9, 55, 104, 253, 262, 336, 346, 498, 545, and 558; landrace such as Ardi-Beniya Ka Bas, Dhodsar local and Desi Bajri-Chomu	Singh et al., 1997; Khairwal and Yadav, 2005; Thakur et al., 2006; Sharma et al., 2007


	N	(%)

Uterine atony	179	(55)

Placenta abnormalities;	173	(53)

 Retained	54	(17)

 Previa	37	(11)

 Abnormally invasive placenta	32	(10)

 Remnant	30	(9)

 Abruption	20	(6)

Laceration;	40	(12)

 Vagina	23	(7)

 Cervix	17	(5)

Uterine rupture	20	(6)

Iatrogenic during/after cesarean	11	(3)

Other	22	(7)

Unknown	9	(3)

	N	(%)

Uterine atony	179	(55)

Placenta abnormalities;	173	(53)

		(1

	N	(%)

Retained	54	7)

Previa	37	(11)

Abnormally invasive placenta	32	(10)

Remnant	30	(9)

Abruption	20	(6)

Laceration;	40	(12)

Vagina	23	(7)

Cervix	17	(5)

Uterine rupture	20	(6)

Iatrogenic during/after cesarean	11	(3)

Other	22	(7)

Unknown	9	(3)


	Apical segment	Middle segment	Basal segment

Wild-type	207 ± 50	253 ± 23	247 ± 27

ugt78d2	194 ± 17	118 ± 14*	142 ± 18*


Feasibility (% of n = 50 valid)	Number (test-retest)	Visit 1, mean (SD)	Visit 2, mean (SD)	t	p	Cohen’s d	ICC


	Standard binary method	Augmented binary method

End point	Fostamatinib 100 mg response rate	Placebo response rate	Difference (95% CI)	Fostamatinib 100 mg response rate	Placebo response rate	Difference (95%CI)


Outcome: any type ofTP53-mutationsin a tumor	HR	95% CI	p-value

Having both disruptiveTP53-mutationsandUGT2B17-deletions	2.22	1.30 to 3.80	0.004

p16-positive tumor	0.53	0.29 to 0.99	0.047

Stage IV	2.32	1.44 to 3.74	0.001

Poorly differentiated tumor grade	1.66	1.01 to 2.74	0.047


	Accuracy	Mean Absolute Error	Area under the ROC Curve

Logistic Regression	80.0%	0.201	0.854

Bayesian Network	96.4%	0.129	0.931

Artificial Neural Network	96.4%	0.045	0.941


	Silica Gels	Zeolites	ALPOS/SAPOS	Composites	MOFs	Activated Carbons

Adsorption heat (kJ/kg)	160 ÷ 180 *	50 ÷ 300*	250 ÷ 300 *	50 ÷ 250*	20 ÷ 200 **	45 ÷ 900 ***

Typical desorption temperatures [°C]	50 ÷ 80	70 ÷ 350	60 ÷ 90	60 ÷ 90	60 ÷ 150	80 ÷ 200

Density (kg/m3)	650 ÷ 700	650 ÷ 900	800 ÷ 900	300 ÷ 600	1000 ÷ 2000	700 ÷ 750

Specific heat (kJ/kgK)	0.8 ÷ 0.9	0.85 ÷ 0.95	0.85 ÷ 0.95	0.95 ÷ 1.05	0.8 ÷ 1.2	0.8 ÷ 1.5

Thermal conductivity (W/mK)	0.15 ÷ 0.20	0.15 ÷ 0.25	0.15 ÷ 0.25	0.15 ÷ 0.30	0.10 ÷ 015	0.15 ÷ 0.75

Possible refrigerants	water	water	water	water, methanol, ethanol	water, methanol, ethanol	methanol, ethanol, ammonia

Amount of uptake exchanged in a typical cyle [g/g]	0.03 ÷ 0.10	up to 0.2	up to 0.25	up to 0.8	0.16 ÷ 0.40	015 ÷ 0.60


	Study 1	Study 2

Location	Newcastle, Australia	Bad Nauheim, Germany

Aim	Develop model, Determine spontaneous recanalization rate	Determine recanalization rates with microbubble + sonothrombolysis enhancement of tPA

Primary Outcome [method]	Recanalization [Laser Doppler]	Recanalization [Laser Doppler]

Secondary Outcome(s) [method]	Infarct Volumes [TTC], Mortality, Neurological Deficit scores	Clot lysis [Inspection of the major branches of the cerebral arterial circulation]

Survival post-embolism	24 h	2 h

Treatment groups (n)	No treatment (n = 7)	Saline (n = 10), tPA (n = 10), tPA + Ultrasound + BR38 microbubbles (n = 10)

Laser Doppler Monitoring	Continuous	Discontinuous

To 4 h post-embolism	Pre-embolism, Post-embolism, Pre-treatment, Post-treatment

	Study 1

Location	Newcastle, Australia

Aim	Develop model, Determine spontaneous recanalization rate

Primary Outcome [method]	Recanalization [Laser Doppler]

Secondary Outcome(s) [method]	Infarct Volumes [TTC], Mortality, Neurological Deficit scores

Survival post-embolism	24 h

Treatment groups (n)	No treatment (n = 7)

Laser Doppler Monitoring	Continuous

To 4 h post-embolism

Study 2

Bad Nauheim, Germany

Determine recanalization rates with microbubble + sonothrombolysis enhancement of tPA

Recanalization [Laser Doppler]

Clot lysis [Inspection of the major branches of the cerebral arterial circulation]

2 h

Saline (n = 10), tPA (n = 10), tPA + Ultrasound + BR38 microbubbles (n = 10)

Discontinuous

Pre-embolism, Post-embolism, Pre-treatment, Post-treatment


RASgrf1	primers	Length (bp)

Segment 1	Forward TTTGTGAGGAAAGATGGTGTTGReverse AAACCATAAAAACCTTCACATAACTAC	349

Segment 2	Forward GTAGAGAAGAGGAAAATAAGGAGGReverse CGAAAACCCCTAAAAATATTACAC	347

RASgrf1	primers	Length (bp)

Segment 2	Forward GTAGAGAAGAGGAAAATAAGGAGGReverse CGAAAACCCCTAAAAATATTACAC	347